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Riassunto 
 
 
La metabolomica è definita come lo studio del metaboloma ovvero del complesso 
sistema di metaboliti che, essendo gli intermedi delle reazioni biochimiche, giocano 
un ruolo importante nella connessione tra i differenti pathways che operano in una 
cellula vivente. 
I metaboliti possono essere visti come il prodotto finale dell'espressione genica o 
dell'attività proteica (enzimi), che definiscono così il fenotipo biochimico di un sistema 
biologico nel suo insieme, compreso l'uomo. Mentre la genomica e la proteomica 
suggeriscono un possibile modo di funzionamento del sistema, la metabolomica dà 
la rappresentazione reale del sistema. 
Similmente a trascrittoma e proteoma, il metaboloma è contesto dipendente e i livelli 
di ogni metabolita dipendono dallo stato fisiologico, patologico e di sviluppo di una 
cellula, tessuto o organismo. A differenza, invece, di quanto accade per m-RNA e 
proteine, è difficile o addirittura impossibile stabilire un link diretto tra geni e 
metaboliti. La natura convoluta del metabolismo cellulare, dove lo stesso metabolita 
può partecipare in molti differenti pathways, complica l’interpretazione dei dati 
metabolici.  
Le analisi di genoma, trascrittoma e proteoma sono basate ognuna sul monitoraggio 
di molecole con simili proprietà chimiche: 4 differenti nucleotidi per genoma e 
trascrittoma, oppure 22 amminoacidi per il proteoma. Questo facilita lo sviluppo di 
approcci analitici “high-throughput”. Nel caso del metaboloma, invece, esiste una 
ampia variabilità in termini di struttura chimica e proprietà dei suoi componenti. 
Difatti, il metaboloma consiste di composti estremamente diversi dal punto di vista 
chimico che vanno da specie ioniche inorganiche a carboidrati idrofilici, alcoli volatili 
e chetoni, acidi organici, lipidi idrofobici e prodotti naturali complessi. Questa 
complessità fa sì che sia impossibile determinare simultaneamente il metaboloma. 
Pertanto, per ottenere più informazioni possibili riguardanti il metaboloma, è 
necessario l’ausilio di efficienti preparazioni del campione e tecniche di estrazione 
selettiva combinate a differenti tecniche analitiche. 
Un approccio analitico importante nel campo della metabolomica è rappresentato 
dall’uso di tecniche di analisi quantitativa come la spettrometria di massa. 
I più importanti vantaggi delle spettrometria di massa sono l’alta sensibilità, selettività 
ed "high-throughput". Inoltre, la sua possibile combinazione con tecniche di 
separazione, come la cromatografia, consente di migliorare la capacità di analizzare 
campioni biologici altamente complessi. Generalmente, le applicazioni di 
spettrometria di massa riguardano l’analisi di piccoli metaboliti come acidi organici, 
amminoacidi, acidi grassi, steroidi ed i loro coniugati; peptidi, proteine e glicoproteine 
e oligonucleotidi derivati da biopolimeri (DNA, RNA).  
L’analisi del metaboloma ha assunto negli ultimi anni un ruolo clinico importante 
nell’identificazione di “disordini” nel profilo metabolico di un paziente. Difatti, la 
valutazione qualitativa e quantitativa, contemporanea ed in funzione del tempo, di un 
consistente numero di metaboliti, come quelli determinabili mediante spettrometria di 
massa in fluidi biologici è in grado di fornire, con una accettabile probabilità, la 
descrizione dello stato biochimico attuale di un organismo, fornendo informazioni 
sulle interrelazioni tra i diversi processi metabolici che definiscono lo stato. 
Si possono così determinare attraverso lo studio dei fluidi biologici (come plasma, 
urine, bile e liquido cefalo-rachidiano) nuovi criteri che definiscono lo stato di salute e 
lo stato di malattia sulla base di una valutazione integrata della varianza dei livelli dei 
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metaboliti e dei parametri metabolici sistemici, permettendo di definire lo stato fisio-
patologico in termini sistemici o organo specifici. In tale modo più che prendere in 
considerazione uno o pochi metaboliti con i relativi processi metabolici, la 
metabolomica esamina l’intero profilo metabolico determinato dall’interconnessione 
dei diversi processi.  
A tale scopo la Spettrometria di Massa, attraverso l’utilizzo di metodi di analisi 
matematiche multivariate, rappresenta uno dei mezzi più potenti e più utilizzati per 
l’analisi del metaboloma, permettendo insieme alla genomica funzionale ed alla 
proteomica di aprire nuove strade conoscitive e applicative nel campo della medicina 
ed in particolare nella diagnosi e nel follow-up degli errori congeniti del metabolismo 
(IEMs).  
Si definiscono “errori congeniti del metabolismo” disordini genetici causati da 
alterazioni di una specifica reazione chimica nel metabolismo.  
Attualmente si conoscono circa 400 difetti geneticamente determinati e correlati a 
patologia; singolarmente rari, se considerati nel loro insieme, essi hanno 
un’incidenza relativamente alta. Al giorno d’oggi si ritiene, infatti, che circa 1 neonato 
ogni 200 ne sia affetto.  
La patogenesi di un errore congenito del metabolismo può essere generalmente 
attribuita alla mancanza o perdita di funzione di una proteina mutante, con funzione 
di enzima o di trasporto. La base genetica degli IEMs è estremamente eterogenea e 
può includere alcuni tipi di difetti genetici: una o più mutazioni puntiformi, delezioni o 
inserzioni o riarrangiamenti genomici che possono essere a carico di sequenze 
codificanti o di regolazione. La malattia è generalmente associata al flusso 
metabolico alterato riguardante il “pathway” che è regolato dalla proteina mutante.  
Originariamente la diagnosi degli IEMs veniva fatta attraverso il riconoscimento di 
anormalità in individui che si ammalavano gravemente o che avevano caratteristiche 
dismorfiche o ritardo mentale. Tali disturbi venivano classificati come "congeniti" 
dall’osservazione della ricorrenza nei membri della stessa famiglia. Con 
l’identificazione di specifici enzimi e pathways metabolici, la comprensione dei 
processi fisici alla base degli IEMs si è evoluta. Questa conoscenza è stata 
accompagnata dalla consapevolezza  della possibilità di errori a vari livelli nei diversi 
pathways metabolici. 
In particolare il lavoro di tesi del progetto di dottorato si è articolato nei seguenti 
punti: 
 
1. sviluppo di un metodo “semi-quantitativo” di spettrometria di massa tandem 
per lo screening neonatale degli errori congeniti del metabolismo; 
2. sviluppo e validazione di un metodo rapido di analisi “quantitativa” per il follow-
up di pazienti affetti da Fenilchetonuria. 
 
 
SVILUPPO DI UN METODO “SEMI-QUANTITATIVO” DI SPETTROMETRIA DI 
MASSA TANDEM PER LO SCREENING NEONATALE DEGLI ERRORI 
CONGENITI DEL METABOLISMO 
 
L’interesse per lo screening neonatale di massa si è andato progressivamente 
estendendo in tutto il mondo da quando Robert Guthrie nel 1963 descrisse il metodo 
per lo screening della Fenilchetonuria (disordine del metabolismo della fenilalanina) 
mediante l’utilizzo del saggio enzimatico di inibizione della crescita batterica che da 
lui ha poi preso il nome. 
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La storia dello screening neonatale delle malattie metaboliche ereditarie ha visto una 
continua e positiva modificazione dei limiti legati allo screening fino a sovrapporsi ad 
esame confirmatorio, grazie all’introduzione di nuove tecnologie analitiche, quali la 
spettrometria di massa tandem (MS/MS), che permettono l’esecuzione di tests 
quantitativi e non solo qualitativi. Grazie al basso numero di falsi positivi e alla 
rapidità di analisi, la Spettrometria di Massa Tandem rappresenta  oggi l’alternativa 
più valida al test di Guthrie. Nel corso degli anni, essa, infatti, ha consentito di 
passare dall’iniziale test singolo per Fenilchetonuria, a test di screening di altre 
malattie metaboliche quali amminoacidopatie a più bassa incidenza, acidurie 
organiche e difetti della β-ossidazione degli acidi grassi. E’ possibile infatti nella 
stessa analisi, a partire da una minima quantità di campione, identificare più di trenta 
errori congeniti del metabolismo.  
Il lavoro del progetto di dottorato è stato finalizzato all’introduzione della tecnologia di 
MS/MS nello screening neonatale degli IEMs. A tale scopo è stato sviluppato un 
metodo analitico basato sull’accoppiamento di un cromatografo liquido (HPLC) ad 
uno spettrometro di massa (Tandem Massa), sfruttando le proprietà fisiche e di 
analisi chimica di entrambi. In particolare, l’uso della tecnica di ionizzazione 
electrospray (ESI) ha consentito di velocizzare e semplificare ulteriormente l’analisi 
accoppiando  allo spettrometro a triplo-quadrupolo un sistema HPLC senza l’utilizzo 
di colonne cromatografiche (FIA-MS/MS). 
Il vantaggio del sistema MS/MS è legato alla sua elevatissima specificità, difatti 
l’analita, indotto a frammentare all’interno dello spettrometro, presenta un pattern di 
frammentazione caratteristico solo di quella molecola. La possibilità di andare a 
monitorare, in maniera selettiva, solo determinate transizioni consente di abbattere 
drasticamente la possibilità di falsi positivi durante l’analisi; inoltre, anche in presenza 
di una matrice molto complessa, questo tipo di indagine strumentale consente di 
isolare uno o più transizioni per uno o più composti eliminando l’interferenza dei 
contaminanti. Ulteriori vantaggi sono l’alta velocità di analisi (solo 3 minuti), l’alta 
riproducibilità e la possibilità di automatizzazione. 
Tale metodo è stato utilizzato per analizzare un campione di circa 250 neonati 
risultati “negativi” allo screening neonatale per la Fenilchetonuria. Dal sangue 
assorbito su carta da filtro di questi “campioni controllo” sono stati estratti metaboliti 
quali amminoacidi ed acilcarnitine generalmente coinvolti nel metabolismo degli 
amminoacidi e degli acidi grassi. Le concetrazioni misurate di ciascun metabolita 
sono state utilizzate per determinare i valori di "cut-off". 
Successivamente, al fine di testare il potenziale diagnostico del metodo analitico 
sviluppato, è stato analizzato un gruppo di pazienti affetti da diversi IEMs. 
Su un totale di 2016 analisi effettuate, solo 33 tests sono risultati “falsi positivi”. 
 
 
SVILUPPO E VALIDAZIONE DI UN METODO RAPIDO DI ANALISI 
“QUANTITATIVA” PER IL FOLLOW-UP DI PAZIENTI AFFETTI DA 
FENILCHETONURIA. 
 
La seconda parte del progetto di dottorato è stata finalizzata principalmente allo 
sviluppo e  alla validazione di un metodo analitico per il follow-up di pazienti affetti da 
Fenilchetonuria. Il metodo si basa su una rapida (3 minuti) separazione 
cromatografica seguita dall’analisi di spettrometria di massa tandem (LC-MS/MS) 
degli amminoacidi fenilalanina e tirosina. 
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Lo studio è stato eseguito su un gruppo di controllo di 24 soggetti e un gruppo di 6 
pazienti affetti da Fenilchetonuria (PKU) la cui diagnosi era stata confermata 
mediante il metodo di analisi “semi-quantitativa” MS/MS su spot per lo screening 
neonatale. 
Il nuovo metodo analitico sviluppato prevede una brevissima preparazione dei 
campioni (10 minuti) che consiste di un’estrazione da campioni di siero degli 
amminoacidi fenilalanina e tirosina seguita dall’analisi LC-MS/MS. 
E’ stata effettuata una validazione del metodo mediante valutazione della resa e 
riproducibilità del processo di estrazione, effetto matrice e linearità. 
Al fine di valutare la capacità del metodo di discriminare tra un profilo metabolico 
“normale” e uno “patologico”, è stato analizzato il siero di 6 pazienti PKU; i risultati 
mostrano una buona risposta “quantitativa” del metodo. Inoltre, messi a confronto i 
risultati delle concentrazioni di fenilalanina e tirosina degli stessi pazienti ottenute sia 
con il metodo di analisi “semi-quantitativa” su spot che con l’analisi “quantitativa” su 
siero liquido, mostrano che entrambi i metodi analitici sono “validi” ad idenitificare la 
patologia anche se il metodo quantitativo su siero "tal quale" mostra risultati più 
interessanti in termini di accuratezza e precisione dell’analisi. 
Questo, insieme alla semplicità e rapidità di esecuzione della preparazione dei 
campioni, rende il nuovo metodo LC-MS/MS una potenziale e valida alternativa 
analitica nel follow-up dei pazienti PKU. 
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Summary 
 
 
Metabolomics is defined as the study of metabolome or the complex system of 
metabolites that, as intermediates of biochemical reactions, play an important role in 
the connection between the different pathways involved in a living cell.  
The metabolites can be seen as the end product of gene expression or activity of the 
protein (enzyme), thus defining the biochemical phenotype of a biological system as 
a whole, including humans. While genomics and proteomics suggest a possible 
mode of operation of the system, metabolomics is the real representation of the 
system.  
In common with the transcriptome and the proteome, the metabolome is context-
dependent, and the levels of each metabolite depend on the physiological, 
developmental, and pathological state of a cell, tissue or organism. However, an 
important difference is that, unlike mRNA and proteins, it is difficult or impossible to 
establish a direct link between genes and metabolites. The convoluted nature of cell 
metabolism, where the same metabolite can participate in many different pathways, 
complicates the interpretation of metabolite data.  
The genome, transcriptome and proteome elucidations are based on target chemical 
analyses of biopolymers composed of 4 different nucleotides (genome and 
transcriptome) or 22 amino acids (proteome). Those compounds are highly similar 
chemically, and facilitate "high-throughput" analytical approaches. Within the 
metabolome, there is, however, a large variance in chemical structures and 
properties. Thus, the metabolome consists of extremely diverse chemical compounds 
from ionic inorganic species to hydrophilic carbohydrates, volatile alcohols and 
ketones, amino and non-amino organic acids, hydrophobic lipids and complex natural 
products. That complexity makes it virtually impossible to simultaneously determine 
the complete metabolome. Therefore, the metabolome has been studied with 
efficient sample preparation and with selective extractions coupled to a combination 
of different analytical techniques to achieve as much information as possible. 
Mass spectrometry (MS) is the most frequently employed method of detection in the 
analysis of the metabolome. The most important advantages of MS are its high 
sensitivity, selectivity and "high-throughput" in combination with the possibility to 
confirm the identity of the components present in the complex biological samples as 
well as the detection and, in most of the cases, the identification of unknown and 
unexpected compounds. Furthermore, the combination of the separation techniques 
(e.g., chromatography) with MS tremendously expands the capability of the chemical 
analysis of highly complex biological samples.  
Usually, the MS applications are distinguished in three basic groups: small 
metabolites such as organic acids, amino acids, fatty acids, steroids and their 
conjugates; peptides, proteins and glycoproteins and oligonucleotides derived from 
biopolymers (DNA, RNA). 
The analysis of metabolomics has taken in recent years an important clinical role in 
identifying "disorder" in metabolic profile of a patient. In fact, the qualitative, 
quantitative and contemporary evaluation depending on the time of a significant 
number of metabolites, such as those determined by mass spectrometry in biological 
fluids, can provide, with an acceptable probability, the description of the biochemical 
present a body. It includes information on the interrelationships between different 
metabolic processes that define the state. You can determine through the study of 
biological fluids (such as plasma, urine, bile and cerebrospinal fluid) new criteria that 
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define the health and status of disease on the basis of an integrated assessment of 
the variance in the levels of metabolites and systemic metabolic parameters, allowing 
the state to define physio-pathological in terms systemic or organ-specific. In this way 
rather than consider one or a few metabolites with metabolic processes, 
metabolomics examine the whole metabolic profile determined through different 
processes. To that end, the Mass Spectrometry, through the use of mathematical 
methods of multivariate analysis, is one of the most powerful and most used for the 
analysis of metabolomics, allowing together with functional genomics and proteomics 
to open new avenues of knowledge and application in field of medicine, particularly in 
the diagnosis and follow-up of inborn errors of metabolism (IEMs). 
Inborn Errors of Metabolism are the genetic disorders caused by alterations of a 
specific chemical reaction in the metabolism. Currently about 400 are known defects 
genetically determined and related pathology. Although individually rare, IEM 
collectively account for a significant proportion of illnesses. Today it is, in fact, that 
about 1 infant every 200 is affected. 
The pathogenesis of an IEM can generally be attributed to the loss- or gain-of-
function of mutant proteins (usually an enzyme or a transporter).  
The genetic basis of IEMs is extremely heterogeneous and can involve any type of 
genetic defect: one or more point mutations, deletions or insertions, or genomic 
rearrangements that may occur in coding or regulatory sequences. Disease is 
generally associated with altered metabolite flux through the pathway that is 
regulated by the mutant protein. 
Originally, the diagnosis of inborn errors of metabolism was generally made by 
observation of recognition of abnormality in people who become ill or had severe 
dysmorphic features or mental retardation and these disorders were understood to 
be inherited by observation of recurrence in family members. With the identification of 
specific enzymes and metabolic pathways, understanding the physical processes 
underlying these IEMs has evolved. This knowledge has been accompanied by an 
awareness of the possibility of errors at various levels in different metabolic 
pathways.  
In particular, the thesis work of PhD project was divided into the following points:  
 
1. “Semi-quantitative” method development by tandem mass spectrometry for the    
newborn screening of inborn errors of metabolism;  
 
2. Development and validation of a rapid method of "quantitative" analysis for the 
follow-up of patients Phenylketonuria affected. 
 
 
“SEMI-QUANTITATIVE” METHOD DEVELOPMENT BY TANDEM MASS 
SPECTROMETRY FOR THE NEWBORN SCREENING OF INBORN ERRORS OF 
METABOLISM  
 
Interest in the neonatal mass screening has been gradually expanding across the 
world from when Robert Guthrie in 1963 described the method for screening of 
Phenylketonuria (disorder of the metabolism of phenylalanine) through the wise use 
of enzyme inhibition of growth bacterial that he has taken the name.  
The history of neonatal screening of inherited metabolic diseases has seen a 
continuous and positive change limits screening to duplicate the examination 
confirmation, through the introduction of new analytical technologies, such as tandem 
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mass spectrometry (MS/MS), which allow testing not only qualitative but also 
quantitative. Thanks to the low number of false positives and speed of analysis, the 
Tandem Mass Spectrometry today represents the most viable alternative to the 
Guthrie test. Over the years, infact it has allowed to move from single test for 
Phenylketonuria to multiple screening tests for other diseases such as metabolic 
aminoacidopathies a lower incidence, organic acidurias and defects of fatty acid 
oxidation.You can, in fact, in the same analysis and with a small amount of sample, 
identify more than thirty inborn errors of metabolism.  
The work of PhD project has been finalized at the introduction of technology MS/MS 
in the newborn screening of IEMs. For this aim, was developed an analytical method 
based on the combination of a liquid chromatography (HPLC) with a mass 
spectrometer (Tandem Mass), exploiting the physical properties and chemical 
analysis of both. In particular, the use of electrospray ionization (ESI) technique 
allows for faster and further simplifies the analysis matching the spectrometer to a 
triple-quadrupole HPLC system without the use of chromatography columns (FIA-
MS/MS). 
The advantage of the MS-MS system is linked to its high specificity, in fact, the 
analyte led to fragmentation within the spectrometer has a characteristic pattern of 
just fragmentation of the molecule. The possibility of going to selectively monitor only 
certain transitions can drastically cut down the possibility of false positives during the 
analysis, and, even if there is a very complex matrix this type of survey instrument 
allows you to isolate one or more transitions to a or more components by eliminating 
the interference of contaminants. Further advantages are high speed analysis (only 3 
minutes), high reproducibility and the possibility of automation. This method was 
used to analyze a sample of some 250 newborns results "negative" neonatal 
screening for phenylketonuria. Absorbed by the blood on filter paper of these "control 
samples" were extracted metabolites such as amino acids and acylcarnitines 
generally involved in the metabolism of amino acids and fatty acids. Measured 
concentrations of each metabolite were used to determine the "cut-off" values. 
Subsequently, in order to test the diagnostic potential of the analytical method 
developed, was analyzed a group of patients with different IEMs. Out of a total of 
2016 tests carried out, only 33 tests are “false positives”. 
 
 
DEVELOPMENT AND VALIDATION OF A RAPID METHOD OF “QUANTITATIVE” 
ANALYSIS FOR THE FOLLOW-UP OF PATIENTS PHENYLKETONURIA 
AFFECTED. 
 
Second part of the PhD project was designed mainly to the development and 
validation of an analytical method for the follow-up of patients Phenylketonuria 
affected (PKU). The method is based on a rapid (3 minutes) chromatographic 
separation followed by tandem mass spectrometry analysis of phenylalanine and 
tyrosine amino acids.  
The study was conducted on a control group of 24 subjects and a group of 6 
phenylketonuric patients whose diagnosis had been confirmed previously by the 
"semi-quantitative" MS/MS analytical method for newborn screening using spot 
samples.  
The new analytical method developed provides a rapid sample preparation (10 
minutes) which consists of extraction from serum samples of the amino acid 
phenylalanine and tyrosine followed by LC-MS/MS.  
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Also was made a method validation by assessing the recovery and reproducibility of 
the extraction process, matrix effect and linearity. In order to assess the ability of the 
method to discriminate between a metabolic "normal" and a "pathological" profile, 
was analyzed the serum of 6 PKU patients. The results show a good "quantitative" 
response of the method. Furthermore, comparison of the concentration results of 
phenylalanine and tyrosine obtained with "semi-quantitative" analysis using spot 
samples with those obtained by "quantitative"  analysis" using liquid serum shows 
that both analytical methods are "reliale" to identify a disease but the quantitative 
method using liquid serum shows the most interesting results in terms of accuracy 
and precision analysis. This, together with the ease and speed of execution of 
sample preparation, makes the new LC-MS/MS method a potential analytical 
alternative for the follow-up of PKU patients. 
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Abbreviations 
 
 
 
IEM    Inborn Error of Metabolism 
PKU    Phenylketonuria 
ESI    Electrospray ionization 
MALDI  Matrix Assisted Laser Desorption/Ionization 
UV    Ultraviolet 
NMR   Nuclear Magnetic Resonance 
MS    Mass Spectrometry 
MS/MS  Tandem Mass Spectrometry 
FIA    Flow Injection Analysis 
HPLC   High Performance Liquid Chromatography 
LC    Liquid Chromatography 
Q    Quadrupole 
QIT    Quadrupole Ion Trap 
LIT    Linear Ion Trap 
TOF    Time of Flight 
FTICR  Fourier Transform Ion Cyclotron Resonance 
GC    Gas Chromatography 
CE    Capillary Electrophoresis 
CID    Collision Induced Dissociation 
GD    Gaucher Disease 
NBS    Newborn Screening 
FAB    Fast Atom Bombardment 
NL    Neutral Loss 
PI    Precursor Ion 
SRM   Single Reaction Monitoring 
MRM   Multiple Reaction Monitoring 
TPN    Total Parenteral Nutrition 
TNT    Transient Neonatal Tyrosinemia 
FAO    Fatty Acid Oxidation 
PAH    Phenylalanine Hydroxylase 
HPA    Hyperphenylalaninemia 
LNAA   Large Neutral Amino Acid 
CVD    Cardiovascular Disease 
LDL    Low Density Lipoprotein 
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Chapter 1 
 
Introduction 
 
 
1.1 Metabolomics 
 
The term “metabolomics” has been used to define the “metabolome” that is the 
complete set of metabolites. Being the intermediates of biochemical reactions, 
metabolites play a very important role in connecting the many different pathways that 
operate within a living cell.  
The levels of the metabolites are determined by the concentration and the properties 
of the enzymes, and their level is, therefore, a complex function of many different 
regulatory processes inside the cell; i.e., regulation of transcription and translation, 
regulation of protein-protein interactions, and allosteric regulation of enzymes 
through their interaction with metabolites. Thus, the level of metabolites represents 
integrative information of the cellular function, and, hence, defines the phenotype of a 
cell or tissue in response to genetic or environmental changes. Adding further to the 
complexity is the fact that many intracellular metabolites participate in a large number 
of different biochemical reactions, and, hereby, the many different parts of the cellular 
metabolism together as a tightly controlled metabolic network (Nielsen, 2003).  
Analysis of cellular function at the molecular level requires recruitment of several 
different analytical techniques. Whereas comprehensive methods for analysis at the 
transcriptional level (transcriptome) and at the translational level (proteome) are 
currently in a rapid state of development, and high throughput analytical methods are 
already in use (Godovac-Zimmermann & Brown, 2001; Baldi & Hatfield, 2002; 
Cristoni & Bernardi, 2003), methods for analysis of the metabolomic approaches are, 
however, so far less common. Although metabolite profiling has long been applied for 
medical and diagnostic purposes (Horning & Horning, 1971; Gates & Sweeley, 1978) 
as well as for phenotypic characterization (Frisvad & Filtenborg, 1983), it is not until 
recently that increasing efforts have been undertaken to develop methods to screen 
a high number of intracellular metabolites in the context of functional genomics 
(Fiehn, 2001; Trethewey, 2001). Increases in mRNA levels do not always correlate 
with increases in protein levels (Gygi et al., 1999), and once translated a protein may 
or may not be enzymatically active. (Sumner et al., 2003) Therefore, changes 
observed in the transcriptome or in the proteome do not always correspond to 
phenotypic alterations (Figure 1). Thus, measurement of metabolites synthesized by 
a biological system, “the metabolome”, constitutes an important complement to 
assess genetic function (Oliver, 1997; Oliver et al., 1998; Hellerstein, 2004). 
In common with the transcriptome and the proteome, the metabolome is context-
dependent, and the levels of each metabolite depend on the physiological, 
developmental, and pathological state of a cell, tissue or organism. However, an 
important difference is that, unlike mRNA and proteins, it is difficult or impossible to 
establish a direct link between genes and metabolites. The convoluted nature of cell 
metabolism, where the same metabolite can participate in many different pathways, 
complicates the interpretation of metabolite data. In addition, for complex organisms 
such as plants, there are more metabolites than genes in a biological system 
(Schwab, 2003), whereas for microorganisms there are generally fewer metabolites 
than genes (Forster et al., 2003). Multiple mRNAs could be formed from one gene, 
multiple proteins from one mRNA and multiple metabolites may be formed from one 
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enzyme, because many enzymes may accept more than one substrate, although 
enzymes generally have high selectivity. Metabolome analysis covers the 
identification and quantification of all intracellular and extracellular metabolites with 
molecular mass lower than 1000 Da, using different analytical techniques. In addition 
to applications in functional genomics, quantification of metabolite concentrations 
enables identification of the kinetics that underlies specific intracellular reactions 
(Bulchholz et al., 2002; Hellerstein, 2004). Together with the structure of a metabolic 
network, the levels of the intracellular metabolites represent key information to 
gaining understand about how the fluxes through different intracellular metabolites 
are regulated; information is valuable not only in functional genomics but also in the 
development of efficient cell factories through metabolic engineering (Nielsen, 2001, 
2003; Hellerstein, 2004). 
The genome, transcriptome and proteome elucidations are based on target chemical 
analyses of biopolymers composed of 4 different nucleotides (genome and 
transcriptome) or 22 amino acids (proteome). Those compounds are highly similar 
chemically, and facilitate high-throughput analytical approaches. 
 Within the metabolome, there is, however, a large variance in chemical structures 
and properties. Thus, the metabolome consists of extremely diverse chemical 
compounds from ionic inorganic species to hydrophilic carbohydrates, volatile 
alcohols and ketones, amino and non-amino organic acids, hydrophobic lipids and 
complex natural products. That complexity makes it virtually impossible to 
simultaneously determine the complete metabolome. Therefore, the metabolome has 
been studied with efficient sample preparation and with selective extractions coupled 
to a combination of different analytical techniques to achieve as much information as 
possible. 
 
Figure 1. The complex interrelationship between the genome, transcriptome (the relative 
concentrations of RNA molecules) proteome (the relative concentration of proteins), interactome (the 
nature of protein–protein interactions) and metabolome (the concentrations of the metabolites that 
exist in any metabolic and environmental state). Alterations in any of these levels of control might 
influence the final phenotype. 
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1.2 Metabolome analysis  
 
 
1.2.1 Target analysis and metabolite profiling 
 
For the analysis of metabolome, there are basically only two different strategies 
(Fiehn, 2002): target analysis and metabolite profiling (Figure 2). 
Generally, target analysis is restricted to quantitative analysis of a class of 
compounds that are related to a specific pathway or to intersecting pathways. 
Targeted analysis is very useful for the study of the primary effect of a genetic 
alteration, and the analytical procedures must include identification and absolute 
quantification of the selected metabolites in the sample. Metabolite profiling or 
metabolic profiling involves rapid analysis, often not quantitative, of a large number of 
different metabolites with the objective to identify a specific metabolite profile that 
characterizes a given sample. This approach can be sub-divided into (a) metabolic 
fingerprinting and (b) metabolic footprinting. Fingerprinting covers the scanning of a 
large number of intracellular metabolites detected by a selected analytical technique 
or by a combination of different techniques in a defined situation (Villas-Boas et al., 
2005). Not all metabolites must be identified and quantified, and “raw” data can be 
used; i.e., one may use the information content from mass spectrometry (MS) profiles 
or nuclear magnetic resonance (NMR) spectra directly, but the method must give a 
reproducible profile of the sample. 
 
 
 
Figure 2. Metabolome analysis in the context of functional genomics. Nu, nucleus; Cit, cytoplasm 
 
 
Metabolic footprinting is more recently proposed approach (Allen et al., 2003), which 
is technically similar to fingerprinting, but is focused on the measurements of all 
extracellular metabolites present in a spent culture medium. The compounds 
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determined are metabolites secreted by the cells into the medium and the medium 
components biochemically transformed by the organism.Both approaches of 
metabolite profiling can be used to distinguish between different physiological states 
of wild-type strains, and between single-gene deletion mutants from even nominally 
closely related areas of metabolism.Important physiological informations can be 
extracted using these approaches but it requires identification of the individual 
metabolites analyzed and it is often laborious and difficult. 
 
 
1.2.2 Measurement techniques 
 
Mass spectrometry (MS) and NMR are the most frequently employed methods of 
detection in the analysis of the metabolome.  
NMR in particular, is very useful for structure characterization of unknown 
compounds and has been applied to the analysis of metabolites in biological fluids 
and cells extracts (Shockcor et al., 1996). 
However, in certain circumstances, the 1H NMR spectrum is insufficient on its own to 
provide information that can fully characterize a metabolite. This limitation is 
obviously the case where analytes contain functional groups that are deficient in 
protons or where the protons can readily chemically exchange with the solvent; the 
signals are broadened beyond detection.  
Alternatively, other nuclei can also be used; such as 13C NMR for labeled metabolites 
(Shockcor et al., 1996; Des Rosiers et al., 2004). However, 13C NMR presents 
relatively low sensitivity; i.e., in the range of µmol to mmol.  
In addition, 13C NMR analysis may take several hours for a single sample, as a 
consequence of its low sensitivity (Des Rosiers et al., 2004) and the equipment costs 
are much higher compared to MS based techniques. 
The most important advantages of MS are its high sensitivity, selectivity and high-
throughput in combination with the possibility to confirm the identity of the 
components present in the complex biological samples as well as the detection and, 
in most of the cases, the identification of unknown and unexpected compounds. 
Furthermore, the combination of the separation techniques (e.g., chromatography) 
with MS tremendously expands the capability of the chemical analysis of highly 
complex biological samples.  
The basic information of mass spectra is characterized by its simplicity. The spectrum 
displays masses of the ionized molecule and its fragments reflecting the elemental 
compositions of both fragments/parent. 
 
 
1.3 Mass spectrometry for metabolomics 
 
 
1.3.1 Instrumentation 
 
Mass spectrometry is a well-known analytical tool for measuring the molecular weight 
of a sample or distinguishing molecules by their mass-to-charge ratios (Feng et al., 
2008).  
Mass spectrometers, that are routinely in used for purposes such as drug discovery, 
diagnostics and bio-analyses, can measure the mass of a molecule only after it 
converts the molecule to a gas-phase ion. To do so, imparts an electrical charge to 
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molecules and converts the resultant flux of electrically charged ions into a 
proportional electrical current that a data system then reads. The data system 
converts the current to digital information, displaying a mass spectrum (Feng et al., 
2008). Mass spectrometers are generally composed of three fundamental parts, 
namely the ionization sources, the mass analyzer and the detector (Figure 3). 
Ionization source is the part of mass spectrometer that ionizes the target materials. 
 
 
 
 
 
Figure 3. General components of mass spectrometers 
 
 
The ionization methods employed by the source usually determine what types of 
samples that can be analyzed. Ionization of the sample molecules were largely 
produced by electron impact generating radical ions and more could easily break 
covalent bonds in the molecules generating extensive and reproducible 
fragmentation. As MS technology advanced, “soft” ionization methods started to 
emerge especially the electrospray ionization (ESI) (Fenn et al., 1989) and matrix 
assisted laser desorption/ionization (MALDI) (Karas & Hillenkamp, 1988; Tanaka et 
al., 1988), which revolutionized MS techniques. In both methods, sample molecules 
are ionized with minimal fragmentation. 
In MALDI, the analyte is mixed with a solution of matrix which strongly absorbs a UV 
light and allowed to dry and crystallize. The matrix compound is excited via 
absorption of a pulsed UV laser and imparts the energy to the analyte, resulting in 
desorption and ionization. However, increased laser fluence often results in 
deposition of “excessive” energy, leading to analyte ion fragmentation. The extent of 
the fragmentation can often be controlled by modulating the power of the laser beam, 
allowing this phenomenon to be used analytically as a means of producing 
structurally diagnostic fragment ions. Generally, MALDI surpasses ESI in terms of 
sensitivity and is more tolerant to salts. Superior sensitivity, relative simplicity of 
operation and ease of automation made it a top choice as an analytical technique for 
a variety of proteomics-related applications (Tanaka K. et al., 1987 & Karas M. et al., 
1988). 
ESI, that is considered to be the “softest” ionization methods, uses electrical energy 
to assist the transfer of ions from solution into the gaseous phase before they are 
subjected to mass spectrometric analysis. This transfer involves three steps: (1) 
IONIZATION SOURCE 
      MASS ANALYZER 
         DETECTOR 
Electrospray Ionization (ESI) 
Matrix Assisted Laser Desorption/Ionization 
Quadrupole Ion Traps (QIT) 
Linear Ion Traps (LIT) 
Time-of-Flight (TOF) 
Fourier Transform Ion Cyclotron Resonance 
Photomultiplier 
Electron Multiplier 
Microchannel Plate 
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dispersal of a fine spray of charge droplets, followed by (2) solvent evaporation and 
(3) ion ejection from the highly charged droplets. Within an ESI source, a continuous 
stream of sample solution is passed through a stainless steel or quartz silica capillary 
tube, which is maintained at a high voltage relative to the wall of the surrounding 
chamber. A mist of highly charged droplets with the same polarity as the capillary 
voltage is generated. The application of a nebulizing gas (e.g. nitrogen) which shears 
around the eluted sample solution enhances a higher sample flow rate. The charged 
droplets, generated at the exit of the electrospray tip, pass down a pressure gradient 
and potential gradient toward the analyser region of the mass spectrometer. With the 
aid of an elevated ESI-source temperature and/or another stream of nitrogen drying 
gas, the charged droplets are continuously reduced in size by evaporation of the 
solvent, leading to an increase of surface charge density and a decrease of the 
droplet radius. Finally, the electric field strength within the charged droplet reaches a 
critical point at which it is kinetically and energetically possible for ions at the surface 
of the droplets to be ejected into the gaseous phase (CS Ho et al., 2003). The 
emitted ions are sampled by a sampling skimmer cone, placed behind the orifice, and 
are then accelerated into the mass analyser where they are separated and resolved 
in according to their mass-to-charge (m/z) ratios. Most commonly used mass 
analyzers include quadrupole (Q), quadrupole ion trap (QIT), linear ion trap (LIT), 
Time-of-flight (TOF), Fourier transform ion cyclotron resonance (FTICR-MS) and 
Orbitrap (Feng et al., 2008).  
Quadrupole mass analyzer uses quadrupole RF fields to selectively filter ions of 
interest based on their mass-to-charge ratio and is closely related to QIT where ions 
are trapped in a 3D quadrupole RF field and then sequentially ejected for separation.  
LIT works in the same mechanism as QIT. However, ions are trapped in a 2D 
quadrupole field instead of a 3D field, which gives LIT higher ion ejection efficiencies 
and ion storage capacities than the QIT method, this advantage of LIT is especially 
significant in working with a continuous ionization source such as ESI where 
increased duty cycles can be achieved. TOF uses electric fields to accelerate ionized 
molecules and then measures the time they take to reach the detector.  
In FTICR-MS, ions are trapped in an analyzer cell composed of electrically 
conductive walls positioned in a homogenous region of a magnet where they are 
excited simultaneously and coherently by a large cyclotron radius. The image current 
produced by the motion of the coherent ions is then recorded and Fourier 
transformed to produce a mass spectrum. In comparison to other mass analyzers, 
FTICR-MS has the capability of analyzing high mass bio-molecules with high 
sensitivity, resolution and mass accuracy. Finally, Orbitrap is a nascent development 
of mass analyzer, which uses a novel approach to measure the mass-to-charge ratio 
of ions, bypassing the need for a superconducting magnet in FTICR-MS. But similar 
to FTICR-MS, Orbitrap also provides high resolving power for each detected peak 
and exceptional mass accuracy (Feng et al., 2008). After ions are separated in the 
mass analyzer, they are subsequently counted by a detector. Analytical results are 
presented in a mass spectrum that is a graphical display of the relative abundance of 
ion signals against the m/z ratios; generally, the highest signal is taken as 100% 
abundance and all the other signals are expressed as a percentage of this.Usually, 
MS is employed in combination with prefractionation methods such as gas 
chromatography (GC), liquid chromatography (LC) and capillary electrophoresis (CE) 
to reduce the complexity of target samples before MS analysis. GC coupled to MS 
has been extensively used in metabolome analysis because of its high separation 
efficiency that can resolve very complex biological mixtures. Only volatile compounds 
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like ketones and alcohols can be examined directly by GC-MS. Analysis of semi-
volatile compounds such as amino acids and lipids require additional chemical 
derivatization processes; this step adds time to the analysis as well as causes more 
complex sample-handling and an increased variance in the analysis. Furthermore, 
heat-labile compounds can not be analyzed and identification of unknown derivatized 
compounds can be difficult because they are chemically modified (Feng et al., 2008 
& Villas-Boas et al., 2005). By combining MS with LC, molecular identification and 
quantification of polar, less-polar and neutral metabolites can be achieved, even 
when they are present at relatively low concentrations levels and in a complex matrix. 
LC-MS can provide information on analytes that display chemical diversities, are 
labile or are difficult to separate at the preparative scale. By using LC-MS, known and 
unknown compounds that are present in a biological matrix can be detected and 
identified without any prior knowledge of their exact chemical structure. LC-MS is 
therefore an important tool for metabolite profiling (Feng et al., 2008, Villas-Boas et 
al., 2005 & Katja D. et al., 2007). CE is a powerful technique for the separation of 
charged metabolites, offering high-analyte resolution. The combination with mass 
spectrometry makes CE-MS an ideal tool for the analysis of the metabolome (Feng et 
al., 2008, Villas-Boas et al., 2005 & Katja D. et al., 2007). (Figure 4) 
 
 
 
Figure 4. Alternative ways for the most used MS analysis of metabolites. The sample can be directly 
analyzed by MS or it can be first resolved with different on-line separation techniques. 
 
MS combined with a separation technique offers tremendous opportunities for 
analysis of complex biological samples because it enables the determination and 
identification of a large number of metabolites in a single analysis. Furthermore, it 
often possible to choose between different methods for analysis of a certain group of 
metabolites (Table 1). However, for metabolome analysis, two issues must be 
considered in connection with choosing an appropriate analysis method: 1) 
scope/resolution, because the metabolome comprises different classes of 
metabolites with distinct physicochemical properties and 2) sensitivity; referring 
mainly to intracellular analysis, where metabolite concentrations are relatively low 
(Katja D. et al., 2007). 
 
 20
 
 
 
 
Analysis  
Technique 
 
Application 
 
Advantages 
 
 
Disvantages 
 
Type  
of Analysis 
 
Reference 
 
GC-MS 
 
Simultaneous 
separation, 
identification and 
quantification of 
different classes of 
metabolites (volatile 
and non-volatile) in a 
single analysis. 
Basically, the type of 
analysis (targeted or 
metabolite profiling) is 
defined by switching 
the detection between 
the SIM and SCAN 
modes. 
 
High chromatographic 
resolution, ideal to 
resolve complex 
biological samples; 
Enable simultaneous 
analysis of different 
classes of metabolites.
 
 Unable to 
analyze thermo-
labile 
metabolites. 
Non-volatile 
metabolites must 
be derivatized 
before analysis. 
Difficult to 
identify unknown 
compounds after 
derivatization. 
 
Targeted Analysis 
Sulfaraphane nitrile 
 
 
 
 
 
Metabolite Profiling 
All different classes of 
metabolites 
  
Chang et 
al., 1998 
Kube et al., 
1999 
 and others. 
 
 
Nilsson et 
al., 1996 
Baldizsar et 
al., 1998 
Villas-Boas 
etal.,2003 
and others 
  
LC-MS 
  
Separation, 
identification and 
quantification of a very 
broad group of 
metabolites. Limited 
potential in 
identification unless a 
MS/MS technique is 
used.  
 
High sensitivity; 
Average to high 
chromatographic 
resolution; No 
derivatization 
required; Enable 
analysis of thermo-
labile metabolites. 
 
A few restrictions 
on LC eluents. 
De-salting may 
be needed; 
Limited structural 
information; 
Matrix Effect. 
 
Targeted Analysis 
Glucosinolates 
 
 
 
Metabolite Profiling 
Glycolytic, 
Intermediates, 
Nucleotides, 
isoprenoids 
  
Mellon et 
al., 2001 
 
 
 
Buchholz et 
al.,2001;  
van Darn et 
al.,2002; 
Cogne et 
al., 2003; 
Novak et 
al., 2003. 
  
CE-MS 
 
Separation, 
identification and 
quantification of polar 
metabolites, using 
small sample volumes. 
  
Useful for complex 
biological samples. 
Small volumes. High 
resolution. 
 
Complex 
methodology and 
quantification; 
Buffer 
incompatibility; 
Difficulty in 
interfacingh; 
Nedd further 
development. 
 
Targeted Analysis 
Oligosaccharides, amino 
acids, 
glycoalkaloids. 
 
 
 
 
 
 
 
 
Metabolite Profiling 
Carboxylic acids, 
phosphorylated 
saccharides, nucleotides. 
 
 
Che et al., 
1999. 
Soga & 
Heiger 
2000 
Biance et 
al., 2003 
Scultz & 
Moini 2003 
 
 
 
Soga et al., 
2002 
 
 MS 
  
The application varies 
according to the 
ionization method. 
Generally applied for 
determination of 
metabolites by their 
molecular mass and 
fragmentation pattern. 
Usually applied in 
metabolite profiling 
without any 
quantification and 
identification of the 
metabolites. 
 
  
Rapid screen of 
metabolites; 
Negligent sample 
clean-up for 
metabolite profiling; 
High sensitivity; 
Recommended for 
identification of 
unknown 
compounds (MS-
MS). 
 
Identification of 
metabolites 
requires MS-MS; 
Matrix Effect; 
Incompatibility 
with higher ionic 
strength (used in 
some metabolite 
extractions). 
 
Targeted Analysis 
Acylcarnitines 
Amino acids 
Carbohydrates 
 
 
 
 
Metabolite Profiling 
No identification 
Chace et 
al., 1997 
Wittmann & 
Heinzle 
2001 
Nagy et al., 
2003 
 
 
Castrillo et 
al., 2003 
Allen et al., 
2003 
 
 
Table 1 Different analytical methods of analysis 
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1.3.2 Tandem MS 
 
Ion dissociation can often be carried out in the ionization source, for example, by 
increasing the skimmer potential in the ESI interface or by using high laser power in 
MALDI. In most cases, however, the sample to be analyzed is a rather 
heterogeneous mixture and the “in source” fragmentation spectrum would be very 
difficult to interpret due to the presence of fragment ions derived from different 
“precursor” ions. A flexible and powerful solution to this problem utilizes a mass 
spectrometer itself as an ion separation device, which allows the fragmentation of 
mass-selected precursor ions to be carried out in a variety of ways. This approach, 
that implies physical separation of the precursor ion prior to fragmentation, was 
pioneered by McLafferty and is known as tandem mass spectrometry or MS/MS 
(McLafferty F. W., 1980).  
In Tandem MS, two (or more) mass analyzers are incorporated and separated by a 
collision cell where selectively isolated parent ion from the first analyzer is 
fragmented for subsequent analysis in the second one.  Although ion trap instrument 
are capable of multiple MS/MS functions (MSn), the technique is most commonly 
performed using a triple quadrupole mass spectrometer. 
Generally, a quadrupole mass analyser is an assembly of 4 parallel metal rods 
kepted at equal distance (Figure 5).  
 
 
Figure 5. Quadrupole Mass Analyser. The ion (M+) travels from the source through the 4 metal rods 
arrangement in the unique oscillating pattern and reaches the detector. 
 
 
Each pair of opposite rods is connected electrically. The ion stability of certain m/z 
value depends on RF/DC voltage applied to the quadrupole and masses are 
analyzed via RF/DC scanning. Single quadrupole MS has only one set (“single”) of 
quadrupole (Q1) and lacks the ability to perform tandem mass spectrometry, 
whereas in a typical tandem quadrupole system there are three sets (“triple”) of 
quadrupole (Q1, Q2 and Q3) (Heewon Lee, 2005) (Figure 6).  
In the case of tandem mass spectral analysis using a triple quadrupole mass 
spectrometer, the analyte ion of interest (usually called the precursor ion) is mass-
selected by the first quadrupole (Q1) and allowed to collide with a collision gas 
(usually argon) in a second RF-only quadrupole collision cell (Q2), where the 
precursor ions are activated by collision and undergo further fragmentation. This 
process is known as collision-induced dissociation (CID). The daughter ions resulting 
from CID are related to the molecular structure of the ions and can be monitored by 
third quadrupole mass analyser (Q3) providing structural information of the molecular 
ions. This tandem system is commonly denoted as MS/MS. When Q1 is set to select 
only one specific m/z ratio, it filters out other molecular ions having different m/z 
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ratios. This is a “purification” step inside the MS system, eliminating complicated and 
time-consuming sample purification procedures prior to MS analysis (CS Ho et al., 
2003). 
The following modes of data acquisition are commonly used in a tandem quadrupole 
system (CS Ho et al., 2003): 
 Product scan (daughter scan): Q1 is static allowing only one ion of specific m/z 
 ratio to pass through and Q3 scans the different Cid product ions. This mode 
 can be used for studying molecular structure; for example, amino acids 
 sequencing of a peptide molecule.  
 Precursor scan (parent scan): Q1 scans over a range of possible precursor 
 ions and Q3 is static focusing on one unique product ion resulting from CID of 
 a class of precursor ions. For example, m/z ratio of 85 is a common fragment 
 ion from all the butylated acylacrnitines precursor ions (C2-C18).  
Neutral loss: both Q1 and Q3 scan together at a constant difference in m/z 
 ratio. This is used to monitor the loss of a neutral fragment for a class of 
 molecules from CID. For example, there is a neutral loss of 102 from most of 
 the butylated amino acids.  
 Multiple reaction monitoring: both Q1 and Q3 are static for a pre-determined 
 pair of precursor and product ions. This confers the highest selectivity and 
 sensitivity and is commonly used in ESI-MS/MS quantification procedures. 
 
 
 
Figure 6. Schematic diagram of a triple quadrupole system. The first (Q1) and the third (Q3) are mass 
spectrometers and the centre (Q2) is a collision cell. 
 
 
 
1.4 Metabolomics and Inborn errors of metabolism 
 
Metabolome analysis is essential to find disorders on a patient’s metabolite profiles 
and should be added as a clinical tool of diagnosis, follow-up and pathophysiological 
analysis. Most clinical diagnoses measure enzyme activities in the patient’s blood but 
the enzyme activity data are not sufficient to detect and predict any disorders in a 
patient’s metabolite profile.  
Suppression or activation in enzyme activity does not always result in the 
accumulations or reductions of its substrates and products because of the multiplicity 
of metabolic pathway networks and the robustness of metabolite profiles. Such 
metabolite profiles can help study the biochemical mechanisms of diseases when 
they are combined with enzyme activity data. In fact, the combined analysis identifies 
the enzyme reactions and metabolites that are disordered and is indispensable for 
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analysis of physiological and environmental perturbations on the metabolite profile of 
a patient (Takaaki Nishioka, 2005). Loss of enzyme activity by genetic or chemical 
perturbations is critical in the metabolic pathways that have neither bypass nor 
isozyma. It induces a lack of essential metabolites in the pathway downstream and 
results in critical disorders on a predetermined metabolite profile. This is easily 
detected and could be medically treated. However, a loss of one or even more 
enzyme activities in the middle areas of a metabolic pathway network induces no 
serious problem because bypass pathways soon compensate the depletion and 
accumulation of metabolites by supplying and catabolizing them. As the depletions 
and accumulations spread over a network, they can cause critical disorders on the 
metabolite profile (Figure 7).  
These global disorders are thought to be the origin of lifestyle-related metabolic 
diseases. Collecting the metabolite profiles of the patients and monitoring their 
metabolite profiles during follow-up is therefore necessary (Takaaki Nishioka, 2005). 
 
 
 
 
 
 
1.4.1 Inborn errors of metabolism (IEMs) 
 
In the early 1900s, Garrod coined the term “Inborn Errors of Metabolism” (IEM) to 
describe genetic disorders that are caused by alterations of a specific chemical 
reaction in metabolism (Garrod A., 1908). Although individually rare, IEM collectively 
account for a significant proportion of illnesses, particularly in children. In an 
Australian study, the prevalence of IEM as detected by newborn screening with 
tandem mass spectrometry was 15.7 per 100,000 births (Wilchen B. et al., 2003). 
IEM can be pleiotropic and can involve virtually any organ or system. Initial clinical 
presentation can occur any time from prenatal development through adulthood, and 
specific environmental triggers are crucial to determining an individual patient 
phenotype (Roe C.R., Ding J, 1995). 
Figure 7. Model of lifestyle related-
disease. Crosses are the sites where 
enzyme reactions are inactivated by 
internal or external perturbations. 
When the sites of inactivation are 
few, they do not affect the metabolite 
profile because of the multiplicity and 
regulation of metabolism. When they 
accumulate and spread over a 
metabolic pathway network, they 
affect irreversible, critical disorders 
on the metabolite profile. Sites of 
disorders are different from patient to 
patient depending on their life style. 
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IEM have traditionally been regarded as Mendelian traits that are caused by single-
gene mutations, and have served as important models for understanding 
mechanisms of monogenic disorders. However, as we learn more about the natural 
histories of IEM, we increasingly recognize that they represent the best examples of 
complex gene-environment interactions and, more specifically, gene-nutrient 
interactions that lead to complex disease (Dipple K.M., McCabe E.R., 2000). IEMs 
are therefore a potentially powerful means to dissect both monogenic and common 
multifactorial diseases.  
Many complex diseases can be perceived as specialized cases of IEM that originate 
from impairment of several steps in different biochemical pathways, each step being 
less severely affected compared to traditional Mendelian disorders. Therefore, the 
net effect of a complex IEM on the organ and organism levels is the alteration of one 
or more metabolite fluxes. A metabolic flux is defined as the production or elimination 
of a quantity of metabolite per mass of organ or organism over a specific time frame 
(mole/kg/hr). In a classic IEM, one primary metabolite flux is affected. In a complex 
disease, a network of metabolite fluxes might be subtly altered to cause a phenotype 
(Brendan L. et al., 2006) (Figure 8).  
 
 
 
 
Figure 8. Inborn errors of metabolism and metabolic networks. Affected pathways are shown in 
red and the degree of involvement is represented by proportional line thickness. In the case of a 
classic inborn error of metabolism, one primary metabolic pathway is affected. In the case of complex 
disease, numberous pathways are affected in a more subtle fashion. 
 
 
1.4.2 IEMs: classification, diagnosis and treatment 
 
IEMs can be categorized according to the affected organ (as in “neurological” or 
“hepatic” diseases), the affected organelle (for example, “mitochondrial”, 
“peroxisomal” or “lysosomal” disorders) or the age of presentation (neonatal or adult-
onset IEM). Because each of these approaches is informative, no single, universal 
classification system exists (Brendan L. et al., 2006). One of the more illuminating 
classification systems has been the separation of IEM into disorders that involve 
large or small molecules (Applegarth D.A. et al., 1989) (Table 2). This classification 
system captures the wide spectrum of pathophysiology, clinical presentation and 
clinical management of inborn errors. Large-molecule diseases are generally 
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associated with a gradual onset of disease. By contrast, acute onset with remitting 
clinical course is often seen in small-molecule diseases.  
The pathogenesis of an IEM can generally be attributed to the loss- or gain-of-
function of mutant proteins (usually an enzyme or a transporter).  
The genetic basis of IEMs is extremely heterogeneous and can involve any type of 
genetic defect: one or more point mutations, deletions or insertions, or genomic 
rearrangements. Mutations can occur in coding or regulatory sequences, and 
mutations in different genes can phenocopy each other by affecting the same 
pathway. Disease is generally associated with altered metabolite flux through the 
pathway that is regulated by the mutant protein (Brendan L. et al., 2006). 
The biological effects of IEM mutations can be mediated by four main processes: 
direct toxicity of accumulating upstream metabolites; deficiency of downstream 
metabolites, that is, downstream substrate deficiency; feedback inhibition or 
activation by the metabolite on the same or different pathway; and diversion of 
metabolic flux to secondary pathways (Figure 9).  
IEM might cause biochemical derangement, the effect of which might be systemic or 
localized to a specific organ or tissue. 
Before an understanding of metabolic pathways developed, originally, the diagnosis 
of inborn errors of metabolism was generally made by observation of gross 
abnormalities. Disorders were originally recognized in individuals who became 
severely ill, or who had dysmorphic features or mental aberrations, and these 
disorders were understood to be inherited by observation of recurrence in family 
members. With the identification of specific enzymes and metabolic pathways, our 
understanding of the physical processes causing these inherited metabolic disorders 
evolved.  
This knowledge was accompanied by the concomitant understanding of the 
possibility for errors at various stages in those pathways. It was recognized that 
deficient enzymes could be identified in individuals by analysis of body fluids and 
measuring the accumulation of substrate for that enzyme, or the accumulation of 
unusual products of pathways utilized in response to the enzymatic block (Brendan L. 
et al., 2006). 
Genomic and proteomic approaches to the primary clinical diagnosis of metabolic 
disease have been largely disappointing. Clear genotype-phenotype correlations 
have rarely been seen in IEM, so the primary method for disease evaluation and 
diagnosis has been through the analysis of metabolites.Genome, transcriptome and 
proteome profiling technologies each monitor molecules that have similar chemical 
properties. By contrast, the metabolome is comprised of chemically heterogeneous 
molecules that vary in different environmental states.  
Genomics and proteomics studies are generally carried out using microarrays and 
2D gels or mass spectrometry, respectively, but the technique of choice is less 
obvious in the area of metabolomics, given the chemical heterogeneity.  
There are several ways to diagnose an IEM, which depends on the specific disorder 
or presenting phenotype.  Generally, measurements of metabolites in various body 
fluids are obtained: organic acids in urine, amino acids in the plasma and fatty-acid-
conjugation products (acylcarnitines) are commonly used to screen for the 
accumulation of substrates that are upstream of a biochemical blockage or the 
deficiency of down-stream products. 
Metabolic profiles that are obtained by these means, however, are necessarily 
incomplete, as each technique might only assay a specific class of compound. These 
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tests might then lead to assay for more disease-specific enzyme activity, gene 
sequencing or other diagnostic procedures (Brendan L. et al., 2006). 
 
 
Figure 9. Pathogenetic mechanism in the inborn errors of metabolism. The effect of an 
enzymatic blockage results in: (a) direct toxicity of the accumulating upstream substrate (S); (b) 
deficiency of the downstream product (P); (c) activation of alternative pathways; (d) diversion of 
metabolic flux to secondary pathways and alternative metabolite (C) production. Large-molecules 
diseases often arise from the aberrant synthetic or degradative processing of polymeric molecules, for 
example, glycoproteins and glycolipids. Small-molecules diseases often involve small organic acids, 
amino acids, glucose, fatty acids, nucleotides and ammonia. In recent years, it has become clear that 
deficiencies of intermediary metabolites can also affect the overall activity of a specific biochemical 
pathway and that this can be caused by the altered transport of metabolites within the cell and/or 
outside the cell. For example, primary carnitine deficiency which is caused by a defect in a carnitine 
transporter that is expressed in the kidney can lead to secondary inhibition of the urea cycle and 
hyperammonaemia. 
 
 
A broader, metabolomics approach can be obtained by using quantitative techniques 
such as mass spectrometry and nuclear magnetic resonance spectroscopy (NMR 
spectroscopy) (Dunn W.B. et al., 2005). In particular, the utilization of mass 
spectrometers in clinical laboratories is undergoing considerable expansion at the 
outset of the 21st century. This expansion is largely due to extraordinary advances in 
mass spectrometry (MS) developed in the previous decade. The number and type of 
clinically significant biomolecules and their analysis using MS are considerable. 
Usually, the clinical applications of MS is distinguished in three basic groups: small 
metabolites such as organic acids, amino acids, fatty acids, steroids and their 
conjugates; peptides, proteins and glycoproteins and oligonucleotides derived from 
biopolymers (DNA, RNA) (Chace D.H., 2001). Furthermore, recently, tandem mass 
spectrometry has facilitated the rapid and economical evaluation of a broad spectrum 
of metabolites from small samples, including dried newborn blood spots. This 
approach has enabled the timely diagnosis of many disorders, thereby facilitating 
early institution of therapy. The broad application of tandem mass spectrometry to 
newborn screening will probably also reveal unanticipated intermediate biochemical 
phenotypes, as well as provide insights into their involvement in more complex 
phenotypes. In addition to the quantitative assay of multiple metabolites, functional 
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approaches are needed that incorporate dynamic measurements of the metabolome, 
ideally under steady-state conditions. 
A frequent approach to the diagnosis of IEM is to examine a profile of intermediary 
metabolites that have been extracted from a biological sample at a given time point. 
Ideally, if an enzymatic deficiency is present, metabolites upstream of the blockade 
will accumulate and there will be deficiency of those downstream. However, this 
approach, although useful and convenient in clinical care, is unrevealing when 
studying the higher levels of control and the interaction between metabolic networks. 
This strategy is further complicated by patients with partial, as opposed to null, 
enzymatic activity. In these patients, the biochemical phenotype might be normal until 
a specific physiological or catabolic stress causes decompensation (Brendan L. et 
al., 2006). The maturation in our understanding of metabolomics and metabolic flux 
has allowed a more comprehensive approach to the diagnosis, management and 
therapy of IEM, leading to the improvements in the prognosis and outcome of certain 
disorders. Given the extreme variability of IEM, their management and therapy has to 
be individualized for each patient, based on the patient’s diagnosis and phenotype.  
Certain IEM can be treated effectively with dietary intervention. A classical example 
is Phenylketonuria (PKU), a disorder that is caused by phenylalanine hydroxylase 
deficiency. If phenylalanine is restricted from the diet, the toxic effects of 
phenylalanine accumulation are prevented and patients can develop with normal 
intelligence (Poustie V.J., Rutherford P, 1999). This discovery was central to the 
rationale for instituting newborn screening for metabolic disorders (Guthrie R., Susi 
A., 1963). Dietary restriction of metabolites upstream of the block has become a 
central management strategy for many IEM. Alternatively, dietary supplementation of 
deficient compounds that are downstream of the block might be useful in IEM. For 
certain IEMs, replacement of the deficient enzyme is possible. This has been 
remarkably effective for Gaucher disease (GD) type I, and is now clinically available 
for other storage diseases, including Fabry disease and some of the 
mucopolysaccharidoses (Pastores G.M.,Barnett N.L., 2005). Another approach to 
treating the storage diseases as GD type I has been substrate-reduction therapy. 
Finally, stimulation of alternative pathways for disposal of the accumulation of 
potentially toxic metabolites upstream of the block might be an effective tool in 
chronic management.     
Therapy for IEMs might also involve the replacement of the defective gene. 
Currently, this approach is clinically available in solid-organ (Saudubray J.M. et al., 
1999) or bone-marrow transplants (Pastores G.M., Barnett N.L., 2005). IEM have 
also been an attractive target for virus-mediated gene therapy, as they might respond 
well to organ-specific transduction, although successful clinical translation has eluted 
the field (Mian A., Lee B., 2002 & Brunetti-Pierri N., Lee B., 2005). 
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        Table 2 Classification system of IEMs 
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1.5 Objectives of the research project  
 
The work of thesis project was focused on the analytical methods development for 
the diagnosis of metabolic diseases and was divided as follows: 
 
 
√ “SEMI-QUANTITATIVE” METHOD DEVELOPMENT BY TANDEM MASS 
SPECTROMETRY FOR THE NEWBORN SCREENING OF INBORN ERRORS OF 
METABOLISM  
The tandem mass spectrometry (MS/MS) enables multianalyte detection for a large 
number of metabolic disorders in a single analytical run in order to dramatically 
increase the duty cycle. The metabolic profile has clearly shown improvements in the 
detection of diseases such as phenylketonuria and several new disorders arising 
from errors in fatty acid oxidation and organic acid metabolism. MS/MS is a powerful 
tool for accessing the metabolic status of a newborn and can detect both inborn 
metabolic errors as well as examine the effect of acquired diseases or pharmacologic 
intervention on intermediary metabolism. 
A new analytical method has been developed for the rapid determination of amino 
acids and acylcarnitines in dried blood spots and in serum spots by FIA-MS/MS; the 
most important feature of this analytical method is the ability to detect and quantify a 
very wide range of different metabolites from a single sample preparation and 
injection. 
 
 
√ DEVELOPMENT AND VALIDATION OF A RAPID METHOD OF 
“QUANTITATIVE” ANALYSIS FOR THE FOLLOW-UP OF PATIENTS WITH 
PHENYLKETONURIA 
Phenylketonuria (PKU) is a metabolic disorder caused by a deficiency of 
phenylalanine hydroxylase (PAH), the hepatic enzyme that catalyses the conversion 
of phenylalanine (Phe) to tyrosine (Tyr), using tetrahydrobiopterin (BH4) as a 
coenzyme. Tandem mass spectrometry has been widely advocated in screening for 
Phenylketonuria using dried blood samples. Although dried blood spots can be used 
for quantification of phenylalanine, they are not ideal for the precise quantification 
required for dietary management because of the imprecision of the sample volume 
(Holub M et al., 2006).  
Because of analytical limitations, the analysis of metabolites extracted from spot 
samples has not sufficient statistical power to generate high confidence in the 
precision of the result; therefore, this assay have to consider a semi-quantitative 
analysis (Chace et al., 2001).  
A new analytical method has been developed for the quantification of Phe and Tyr 
levels in serum by liquid chromatography coupled with electrospray tandem mass 
spectrometry. This quantitative LC-MS/MS analysis offers the better precision and 
accuracy, in comparison with the commonly FIA-MS/MS method for neonatal 
screening of Phenylketonuria. This method represents a valide alternative for 
evaluation of therapy in the follow-up of patients. 
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Chapter 2 
 
Introduction 
 
 
2.1 Newborn screening 
 
Mass newborn screening (NBS) via blood spot began in the 1960s when Guthrie and 
Susy developed a method for estimation of phenylalanine in blood samples collected 
on a filter paper using a bacterial inhibition assay named “Guthrie test” (Guthrie R., 
Susy A. 1963 & MacCready R.A., Hussey M.G., 1964).  
On the day the newborn is to be discharged from the nursery, a blood specimen, 
obtained from the heel by capillary puncture, is directly impregnated into a filter-paper 
card, and, when dry, mailed to the central laboratory where is execute the “Guthrie 
test” (Figure 1).  
 
 
 
Figure 1. Impregnation of blood from the heel of a newborn into a filter-paper card. 
 
 
 
The principle of this assay is that bacterial growth, which would normally occur in a 
proper medium, is inhibited by an analogue (e.g. B2-thienylalanine) of the amino acid 
in question (e.g. phenylalanine). However, the analogue can itself be counteracted by 
the amino acid so that growth occurs in the presence of the specific amino acid 
(Figure 2). 
An important aspect of this assay is that when the concentration of the inhibiting 
analogue is kept constant, the amount of bacterial growth is directly proportional to 
the concentration of the amino acid.  
In practice, the assay is performed in plastic trays containing agar, a medium 
consisting of various inorganic and organic compounds, bacteria (Bacillus subtilis) 
and a specific inhibitor (analogue). After these materials have been pipetted into the 
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trays and the agar solidified, a disc from each filter-paper blood specimen is punched 
onto the agar.  
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 2. Diagrammatic representation of the mechanism of the "Guthrie" bacterial inhibition assay. In 
this depiction it is suggested that the amino acid competes with the analogue at the level of cellular 
transport. This may be true though it is equally plausible that the competition is at the intracellular 
metabolic level. 
 
Each tray contains, in addition to the newborn blood discs, a row of control blood 
discs containing varying amounts of the amino acid. After complete preparation, the 
trays are incubated at 37°C overnight, following which the growth around each disc is 
observed (Guthrie R., Susy A. 1963) (Figure 3). 
 
 
 
 
Figure 3. A typical "Guthrie' plate for phenylalanine. The second row from the downstairs contains 
dried horse blood filter-paper discs used as controls with concentrations of phenylalanine varying from 
less than 2 mg/100 ml to 20 mg/100 ml. In the third row from the top is a blood specimen from a 
neonate indicating marked hyperphenylaIaninaemia (phenylalanine concentration almost 20 mg/100 
ml). This infant was later proved to have phenylketonuria. 
 
 
This approach was introduced as a way to detect and start early treatment for 
phenylketonuria (PKU), a disorder of amino acid phenylalanine metabolism, to 
prevent the neurodevelopmental problems found in untreated patients. It was so 
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successful that soon thereafter, the screening for PKU was instituted in the entire US 
and many other developed countries (Paul D.B., 1997). 
In the 1970s, the ability to test for congenital hypothyroidism allowed another addition 
to the neonatal blood spot panel. Since then, various disorders were added to state 
NBS panels, one disorder at a time. Each disorder required the development of new 
testing materials and each test was run separately (Paul DB, 2008). Since 1992, in 
Italy it is a routine component of neonatal care to screen infants for congenital 
hypothyroidism, phenylketonuria and cystic fibrosis; the Italian law (law n.104/92) 
provides that the newborn infant is to be subject to newborn screening for these 
diseases between forty eight and seventy second hour of life. The primary aim is the 
early detection and treatment of clinically important disorders in order to minimize 
morbidity and mortality in early childhood. Among the disorders that may be 
diagnosed, some cause severe illness or death within the first few days of life and 
newborn screening may serve only to suggest a diagnosis that might otherwise have 
been missed. However, most of the disorders are treatable if they are diagnosed 
early. With early diagnosis and appropriate treatment, some problems can be 
avoided; these include biochemical disturbances such as hyperammonemia in 
patients with urea-cycle disorders that present after the newborn period, severe 
metabolic acidosis in patients with disorders of organic acids, or hypoketotic 
hypoglycemia, cardiomyopathy or rhabdomyolysis in patients with disorders of fatty-
acid oxidation; if left untreated, these disorders may lead to brain damage, other 
organ damage or death.  
In the 1990s, with the introduction and development of electrospray tandem mass 
spectrometry (ESI-MS/MS) into the metabolic screening laboratories, the paradigm of 
analyzing one analyte per disorder changed, it has become possible to use a single 
test to screen for a wide range of very rare disorders that have not been screened for 
previously. Tandem mass spectrometry is used in many screening programs to 
analyze amino acids and acylcarnitines in blood to detect disorders of amino acids, 
organic acids and fatty-acids metabolism. With a single and “2-3 min” long analysis of 
a small blood spot, MS/MS allows the determination of multiple acylcarnitines and 
amino acids (multiplex testing) characteristic of several metabolic disorders 
(Carpenter KH, Wiley V., 2002 & McCandless SE., 2004) (Figure 4). Where 
previously one blood spot could detect one disorder, it is now possible to detect 
upwards of 80 disorders on a single blood spot (Copeland S, 2008). 
 
 
 
 
Figure 4. Total ion elution profile of amino acids and acylcarnitines extracted from dried blood spot. 
 33
2.2 Historical development leading to the application of MS/MS to newborn    
screening 
 
Before 1980, diagnosis of inborn errors of organic acid or fatty acid metabolism 
usually required gas chromatography (GC) analysis of urine extracts with relatively 
non-specific detectors. Identification of a metabolite in urine was based solely on its 
retention time. The addition of mass spectrometry (MS) to GC applications in the late 
1970s dramatically improved the analysis of organic acids by providing mass spectral 
identification of each compound at a particular retention time. This combined 
technique, known generally as GC/MS, became a gold standard for identification of 
metabolic disorders from urine specimens (Chalmers RA et al., 1982 & Niwa T., 
1986).  
In the mid-1980s, recognition that patients with carnitine deficiency were frequently 
diagnosed with a metabolic disorder heightened suspicion of a possible connection 
between carnitine and disorders of fatty and organic acid metabolism (Chalmers RA 
et al., 1984 & Di Donato S. et al., 1984). At that time, routine investigation of a 
possible metabolic disorder included measurement of plasma and urine carnitine 
concentrations.  
Methods used to measure carnitine, acetylcarnitine (C2) and total carnitine often 
involved enzymatic and radioenzymatic assays, whereas measurement of 
acylcarnitines usually involved HPLC (Marzo A et al., 1997). Carnitine measurement 
generally included free, nonesterified and total carnitine (free plus esterified 
carnitine). Quantification of esterified carnitine was imprecise, calculated by 
substraction of the free carnitine (FC) concentration from total carnitine. Efforts to 
understand carnitine deficiencies, metabolic disorders and Reye syndrome and their 
correlation with free, total and esterified carnitine led to recognition that esterified 
carnitine may be diagnostic. Efforts were made to further investigate carnitine and 
acylcarnitine deficiencies to gain a better understanding of the role of carnitine and its 
fatty acid esters in metabolic diseases (Bieber LL et al., 1986 & Roe CR et al., 1983). 
As a result, the establishment of new methods for carnitine and acylcarnitine 
measurement became important. Eventually, this search for new methods led to the 
development of MS/MS for newborn screening. 
Before the availability of MS/MS, two approaches to the investigation of carnitine and 
acylcarnitines included either hydrolysis of fatty acyl residues from carnitine with 
subsequent analysis by GC/MS, or extensive sample preparation for chemical 
modification of acylcarnitines to facilitate their analysis by GC/MS. Although both 
approaches presented sample preparation and time limitations, they nonetheless 
served to provide integral information about the role of acylcarnitines in metabolic 
diseases. 
The limitations of previous methods led to the search for a simpler and more direct 
method for the measurement of acylcarnitines. As a result, a new form of MS for non-
volatile specimens, known as fast atom bombardment (FAB) MS emerged (Chai WG 
et al., 1987 & Millington DS et al., 1984). With FAB MS, samples are ionized after 
bombardment by a stream of atoms. Unlike the electron impact ionization used in 
GC/MS, FAB MS produces little fragmentation during the ionization process. This 
feature is often referred to as “soft ionization”. After ionization, the mass 
spectrometer detects and quantifies ions in a complex mixture. For the analysis of 
complex biological extracts, however, overlapping and suppressed masses lead to 
mass spectra that are not interpretable and thus uninformative. Consequently, further 
modifications led to the addition of liquid chromatography for separation of 
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acylcarnitines from one another and from other compounds present in a sample 
(Millington DS et al., 1989). The fundamental technologic developments in MS/MS 
application to metabolite analysis initiated in the early 1990s still exist today. 
 
 
2.3 MS/MS detectable disorders 
 
Currently, nation-wide neonatal screening programs in North America, Europe and 
Australia are using automated ESI-MS/MS for metabolic profiling of amino acids and 
acylcarnitines from blood spots. State-of-the-art laboratories can screen several 
hundred samples per day by sampling of blood spots on the Guthrie card, extraction 
of analytes, formation of derivatives, ESI-MS/MS analysis and electronic data 
processing with computer-alert of abnormal results. 
Disorders detected by most MS/MS newborn screening programs can be divided into 
three major categories: amino acid disorders including urea cycle defects, organic 
acid disorders and fatty acid oxidation defects (Garg U et al., 2006) (Table 1).  
  
Table 1. Inherited metabolic disorders detected by newborn screening 
with tandem mass spectrometry
Aminoacidopathies
Phenylketonuria and hyperphenylalaninemias
Tyrosinemia
Maple Syrup urine disease
Homocystinuria
Hypermethioninemia
Nonketotic hyperglycinemia
Hyperornithinemia-hyperammonemia-hyperhomocitrullinuria syndrome
Argininosuccinic acid synthetase deficiency
Argininosuccinate lyase deficiency
Argininemia
Organic Acidemias
Glutaric acidemia type I
3-Hydroxy-3-methylglutaryl-CoA lyase deficiency
Propionic acidemia
Methylmalonic acidemia
Isovaleric acidemia
2-Methylbutyryl-CoA dehydrogenase deficiency
3-Methylcrotonyl CoA carboxylase deficiency
Multiple carboxylase deficiency
Defects of Fatty Acid Oxidation
Short chain acyl-CoA dehydrogenase deficiency
Isobutyryl-CoA dehydrogenase deficiency
Medium chain acyl-CoA dehydrogenase deficiency
Long chain hydroxy acyl-CoA dehydrogenase deficiency
Very long acyl-CoA dehydrogenase deficiency
Multiple acyl-CoA dehydrogenase deficiency
Ethylmalonic acidemia
Β-ketothiolase deficiency
Carnitine palmitoyltransferase I and II deficiency
Carnitine transport defect
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2.3.1 Disorders of amino acid metabolism 
 
 
Tandem mass spectrometry technology can measure the amount of various amino 
acids present in the blood spot. The amino acids on the panel were chosen for their 
ability to indicate the presence of specific disorders. In general, they should be 
detectable after 24 hours of age despite feeding status and, when disease is present, 
will continue to increase with time. External factors can cause false elevations 
including hyperalimentation and liver dysfunction. The presentation of primary 
disorders of amino acid metabolism in general is insidious and slow, and patients do 
not commonly have major metabolic decompensations. However, when untreated, 
the symptoms may present to neurologists as ataxia, mental retardation and 
seizures. Treatment consists of limiting the offending amino acid in the diet and, in 
the case of tyrosinemia type I, blockade of the proximal enzyme step.  
The biochemistry of amino acids is both complex and interdependent (Christenson R 
et al., 1999 & Scriver CR 1995). Physiologically important amino acids, known as α-
amino acids, have many functions in metabolism, serving as building blocks of 
peptides and proteins, precursors to hormone mediators and other functional 
molecules, and sources of energy production. 
Many amino acids are readily interconverted to other amino acids by transamination. 
Metabolism includes conversion of amino acids to ammonia and organic acids by 
deamination. Many inherited disorders of amino acid metabolism are characterized 
by a significant elevation in the concentration of certain amino acids in blood (amino 
acidemias) and urine (amino acidurias), ammonia and organic acids (organic 
acidemias). Abnormal concentrations of amino acids may also be found in blood or 
urine as a result of organ failure and impaired function from diseases or immature 
development.  
In the MS/MS analysis, α-amino acids fragment in a reproducible manner, producing 
a neutral molecule, formic acid. This analysis requires derivatization to enhance 
ionization. The most common derivative is formed by esterification of the carboxylic 
function groups with butanol. These butyl ester derivatives of amino acids fragment 
as a butyl formate with a mass of 102 Da (Figure 5). Hence, the MS/MS analysis 
using an NL 102 Da scan will selectively detect amino acids (Chace D.H., Kalas T.A., 
2005). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Schematic of collision-induced dissociation (CID) of the protonated butyl esters of 
phenylalanine 
Phenylalanine, butyl ester 
Butyl formate 
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NL 102 amino acid analysis acquires the data for phenylalanine (Phe) and other 
important amino acids such as tyrosine (Tyr), leucine (Leu) and methionine (Met) 
simultaneously (Chace D.H. et al., 1993, Chace D.H. et al., 1995 & Chace D.H. et al., 
1996) (Figure 6). 
 
 
Figure 6. Tandem mass spectra of amino acid butyl esters using an NL 102 scan. Profile obtained 
from a blood spot of a normal newborn. The horizontal axis represents mass to charge ratios while the 
vertical axis represents ion intensity expressed as a % of the largest peak in the spectrum. Internal 
standards are represented as smaller italic fonts and underscored. 
 
 
A complete amino acid analysis requires the use of another type of MS/MS scan that 
selectively detects basic amino acids such as glycine (Gly), ornithine (Orn), arginine 
(Arg) and citrulline (Cit) (Figure 7).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Tandem mass spectra of basic amino acid butyl esters using a Selected Reaction 
monitoring scan (SRM). Profile obtained from a blood spot of a normal newborn. 
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This scan, also known as selected reaction monitoring (SRM), is useful in choosing a 
limited set of amino acids by selecting their specific mass values and fragment ions. 
Essentially, the difference between SRM and NL scans is that NL scan displays an 
entire mass range while SRM scans choose only a few mass values (Figure 8). 
Final, the advantage is that no secondary injections, separate sample analysis or 
modifications in sample preparation are required. Neutral Loss and Selected Ion 
Monitoring are all incorporated within the 2-min amino acid analysis (Chace D.H., 
Kalas T.A., 2005). 
 
 
 
 
 
Figure 8. Schematic representation of different scan modes for MS/MS. Neutral loss scan: in this 
scan, first and third mass spectrometers analyze those ions which differ by a certain number of mass 
units (equivalent to a neutral fragment, N). This scan is particularly useful for monitoring a group of 
compounds producing a common neutral molecule such as neutral α-amino acids. Selective reaction 
monitoring: in this scan, all the mass spectrometers are static as they are analyzing only preselected 
ions (A, A1). This scan is particularly useful for quantification as this is the most sensitive of all the 
scans. 
 
 
 
2.3.2 Fatty acid and organic acid disorders 
 
The oxidation of fat plays a major role in energy metabolism especially during fasting 
periods. Fatty acids with carbon chain lengths of primarily 18 carbons or less are 
metabolized in the mitochondria by a process known as β-oxidation (Scriver C.R., 
1995 & Rinaldo P. et al., 1998). They are transported through the cellular membrane 
into the cell cytosol and are translocated across the outer mitochondrial membrane to 
form fatty acylCoA thioesters. The fatty acyl group is transferred to carnitine and 
transported into the inner mitochondrial matrix, where it is transferred back to CoA to 
reform a fatty acyl-CoA plus free unesterified carnitine. The fatty acyl-CoA 
metabolites undergo oxidation by a complex of membrane-bound and matrix-soluble 
enzymes (that are “size” specific), producing acetyl-CoA and fatty acyl-CoA 
thioesters. Each round of metabolism produces a single molecule of acetyl-CoA and 
a fatty acyl-CoA that is two carbons shorter. Acetyl-CoA is converted in the liver to 
other substrates (ketone bodies) that are utilized by other tissues for energy 
metabolism. Very long-chain fatty acids, primarily 20-26 carbons, are metabolized by 
peroxisomal  β-oxidation (Blau N. et al., 1996 & Verhoeven N.M. et al., 1995) (Figure 
9). 
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Intermediates of mitochondrial β-oxidation or peroxisomal β-oxidation are important 
clinical diagnostic markers for many disorders of fatty acid and organic acid 
metabolism.  These mitochondrial fatty acids can be found in blood and plasma and 
detected using methods such as MS/MS.  
This analysis is rapidly becoming the method of choice in newborn and clinical 
screening of inherited disorders of fatty acid oxidation, an important class (20-30 
disorders) of metabolic diseases (Scriver C.R., 1995 & Rinaldo P. et al., 1998).  
These inherited defects can produce hypoglycemia, vomiting, liver disease, 
cardiomyopathy, developmental delay, hypotonia, seizures, coma and premature 
sudden death. Symptoms can occur early in the newborn period through adult life in 
varying degrees of severity. Alternatively, these diseases may be asymptomatic until 
a life-threatening episode. Exacerbation of the fatty acid oxidation disorders occurs 
especially during fast or inadequate caloric intake whereas organic acidemias are 
exacerbated by high protein intake.  
Several disorders in mitochondrial β-oxidation have been characterizated and include 
very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency, medium-chain acyl-
CoA dehydrogenase (MCAD) deficiency, short-chain acyl-CoA dehydrogenase 
(SCAD) deficiency, multiple acyl-CoA dehydrogenase deficiency (MADD, GA-II), 
carnitine transporter defects, long and short-chain hydroxyl-acyl-CoA dehydrogenase 
(LCHAD and SCHAD, respectively) deficiencies, carnitine-palmitoyl transferase type I 
and II deficiencies (CPT-I and CPT II), HMG CoA-lyase and 2,4-dienoyl-CoA 
reductase deficiencies (Scriver C.R., 1995) (Figure 10). 
Disorders of fat metabolism produce significant elevations of free fatty acids in 
plasma. These fatty acids are eliminated in urine predominantly as a conjugate with 
glycine (an acylglycine). Fatty acids in the mitochondria form acylcarnitines and are 
exported into the cell cytosol and plasma. Acylcarnitines are eliminated in bile and 
urine.  
In metabolic disorders, carnitine deficiency results in many cases from the continued 
formation of fatty acylcarnitine and its subsequent loss in urine and bile.  Amelioration 
of these deficiencies may include enhancing elimination of toxic fatty acids as 
acylglycines or acylcarnitines by administration of glycine and carnitine or reducing 
metabolism of fatty acids by restoring and maintaining blood glucose at normal 
levels.  
The MS/MS analysis of acylcarnitines is characterized by a stable product ion at m/z 
99 or m/z 85 for methyl or butyl esters, respectively (Figure 11). On the basis of the 
product ion spectra, all acylcarnitines of the same derivatization technique share a 
common mass for that product ion, e.g. m/z 99 or m/z 85 for methyl or butyl esters of 
acylcarnitines, respectively. Precursor ion (Figure 12) scans are therefore used to 
generate a selective MS/MS analysis of acylcarnitines (Figure 13). 
One of the most important developments that occurred during the 1990s was multiple 
metabolite analysis in a single sample injection. For example, both butyl esters of 
amino acids and acylcarnitines are analyzed concurrently (Figure 14). Furthermore, 
additional scan functions have been developed for free carnitine and basic amino 
acids (Chace D.H. et al., 1999 & Chace D., Naylor E., 1999). These multiple scan 
functions have enabled a comprehensive multiple metabolic profile in newborn 
screening (Naylor E. Chace D.H., 1999). Disorders of amino acid metabolism, 
organic acid metabolism and fatty acid metabolism are measured in a single test.  
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Figure 9. Illustration of β-oxidation and the roles of carnitine and acylcarnitines in metabolism. FA, fatty 
acids; LC, long-chain acyl-CoA; MC, medium-chain acyl-CoA; SC, short-chain acyl-CoA; A, product of acyl-CoA 
dehydrogenase; B, product of enoyl-CoA hydratase; C, product of 3-hydroxyacyl-CoA dehydrogenase; D, product 
of β-ketothiolase; CU, carnitine uptake; AS, acyl-CoA synthase; CT, carnitine translocase.  
 40
 
 
 
 
 
Figure 10. Mitochondrial fatty acid oxidation pathways. Abbreviations: CPT-1 = carnitine palmitoyl 
transferase-1; CPT-2 = carnitine palmitoyl transferase-2; MCAD = medium chain acyl-CoA 
dehydrogenase; MTP = mitochondrial trifunctional protein; SCAD = short chain acyl-CoA 
dehydrogenase; SCHAD = short chain 3-hydroxy acyl-CoA dehydrogenase; VLCAD = very long chain 
acyl-CoA dehydrogenase. MTP, a membrane bound enzyme, has three enzyme activities: long-chain 
3-hydroxyacyl-CoA dehydrogenase, long chain enoyl-CoA hydratase and long-chain 3-oxo-acyl-CoA 
thiolase, and functions to convert long chain fatty acids to medium chain fatty acids. Enzymes/ 
transporters marked with * are generally targeted for detection by MS/MS newborn screening. 
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Figure 11. Butylation and fragmentation of acylacarnitines to yeld a common fragment at m/z 85. 
 
 
 
 
 
 
 
Figure 12. Schematic representation of Precursor ion scan: In this scan, the first mass spectrometer 
allows the transmission of selected ions (A–C) while the third mass spectrometer is set to analyze a 
specific fragment ion (X) generated from the selected ions (A–C). This scan is particularly useful for 
monitoring a group of compounds producing a common ion such as acylcarnitines. 
 
Figure 13. Normal blood acylcarnitine profile obtained by ESI-MS/MS analysis using precursor-ion 
scanning of m/z 85. 
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Figure 14. Multiple metabolic profile of amino acids and acylcarnitines. 
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Materials and Methods 
 
 
2.4 Expanded Newborn Screening programs 
 
Analytical method development, optimization and validation by MS/MS for an 
“expanded newborn screening pilot program” were the first fundamental aim of this 
research project.  
Blood spot samples obtained at 48 to 72 hours of life from all healthy infants born in 
Campania region were tested by tandem mass spectrometry for amino acids and 
acylcarnitines detection. The cut-off values were determined for each analyte. 
After that, was assessed the diagnostic potential of MS/MS method developed. For 
this aim were tested the blood spot samples of patients that were under treatment in 
the pediatric department of polyclinic hospital “Federico II” in Naples. These subjects 
were divided in children that had 1 month of life and in children that are over 1 month 
year old. 
For the first group was necessary a blood spot sample for MS/MS analysis but for 
child over 1 month of life is to be did a venous blood drawing that is to be mailed to 
laboratory where is to be centrifuged and then the serum is to be impregnated on 
filter paper. The treatment of serum specimen for extraction of amino acids and 
acylcarnitines is the same of the blood spot specimen and the same analytical 
method was applied. The cut-off values for amino acids and acylcarnitines from dried 
serum spot were calculated. 
However, it is necessary to consider that, although for most of the conditions 
screened, the sensitivity and specificity of MS/MS is very high, there are false 
positives causing parental stress and consuming health care resources. That is 
because there are different factors contributing to false positive results include 
prematurity or low birth weight, the use of total parenteral nutrition (TPN), nutritional 
modifications and use of medications such as carnitine and pivalic acid. For this 
reason, also the cutoff values for amino acids and acylcarnitines extracted by dried 
blood spots from healthy preterm neonates were determined. 
 
 
 
2.4.1 Sample preparation 
 
From each dried blood filter card a 3 mm spot, containing 3.3 uL of blood, was 
punched and transferred into tubes, where 200 uL of methanol containing deuterated 
amino acids and acylcarnitines standards was added. The concentrations of the 
internal standards were as follows: 15N, 2-13C-Glycine 12.5 µmol/L, 2H4-Alanine 2.5 
µmol/L, 2H8-valine 2.5 µmol/L, 2H3-Leucine  2.5 µmol/L, 2H3-Methionine 2.5 µmol/L, 
2H5-Phenylalanine 2.5 µmol/L, 13C6-Tyrosine 2.5 µmol/L, 2H3-Aspartate 2.5 µmol/L, 
2H3-Glutammate 2.5 µmol/L, 2H2-Ornithine 2HCl 2.5 µmol/L, 2H2-Citrulline 2.5 µmol/L, 
2H4 13C-Arginine HCl 2.5 µmol/L; 2H9-carnitine (free carnitine, CN) 0.76 nmol/mL, 2H3-
acetylcarnitine (C2) 0.19 nmol/mL, 2H3-propionylcarnitine (C3) 0.04 nmol/mL, 2H3-
butyrylcarnitine (C4) 0.04 nmol/mL, 2H9-isovalerylcarnitine (C5) 0.04 nmol/mL, 2H3-
octanoylcarnitine (C8) nmol/mL, 2H9-myristoylcarnitine (C14) nmol/mL, 2H3-
palmitoylcarnitine (C16) 0.08 nmol/mL (stable isotope standards, CIL, Andover, MA, 
USA). These standards were used to quantify amino acids and acylcarnitines that are 
extracted into the methanol. It is important to note that quantification of the 
 44
compounds in a dried blood spot (DBS) is different from clinical analyses that use 
liquid blood, plasma or urine samples. Traditional isotope dilution technique requires 
addition of a stable isotope standard to a liquid blood sample where it can uniformly 
mix with the unlabeled compounds in the original sample. Because the chemical 
properties of the labeled standards and the unlabeled compound are nearly identical, 
all extraction and derivatization procedures will be nearly the same for batch species. 
Because the blood spot is a dry sample, a liquid standard cannot be uniformly mixed 
with the original sample. As a result, adding the standard to the methanol extracts 
causes the loss of a certain degree of accuracy and precision because of variations 
in both blood volumes in the disk and extraction efficiency (Adam B.W. et al., 2000). 
The remainder of the sample preparation after extraction, however, is identical for 
both standard and metabolite. Therefore, this technique is a partial isotope dilution, 
often indicated as “pseudoisotope dilution” (Chace D.H., 2001). 
The samples were vortexed and shaked for 20 minutes. After that, the solvent was 
evaporated under a gentle stream of N2. The most common method for extracted 
metabolite preparation requires esterification that facilitates ionization and improves 
sensitivity. The derivatization requires addition of 75 µL of acidified butanol (3N HCl 
in n-butanol) for butyl esters formation. After incubation at 65°C for 25 minutes, the 
excess derivatization agent was removed under a gentle stream of N2. Just prior to 
MS/MS analysis the specimen was reconstituted in 300 µL of solvent containing 
acetonitrile/water/formic acid (70:30:0.05 by volume) that assist in protonation and 
ionization (Figure 15).  
The same sample preparation was used for dried serum spot specimens. 
 
 
 
 
 
 
 
 
 
Figure 15. Illustration of sample preparation from newborn screening filter paper spot and analysis by 
MS/MS. The sample is prepared and then injected into the MS/MS. In MS-1 ions are separated based 
on their mass to charge ratio. The selected ions enter the collision cell (another mass spectrometer 
with inert gas flow for collision), where fragmentation of selected ions takes place. MS-3 separates 
fragmented ions and presents them to the detector. Data analysis involves ion identification and 
quantification, and flagging of abnormal results. 
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2.4.2 Acylcarnitines and amino acids  profile 
 
 
Acylcarnitines and amino acids were analyzed as butyl esters on an API 2000 triple 
quadrupole tandem mass spectrometer (Applied Biosystems, Sciex, Concord, 
Ontario, Canada) with an electrospray source. For analysis, of each reconstituted 
specimen were injected 60 µL into a flowing stream of solvent (50 µL/min).  
Solvent delivery is via high performance liquid chromatography binary pump (HPLC 
Agilent 1100) with no chromatography, a method called “flow injection analysis” 
(FIA). The stream teminated in a spray that was charged at 5500 volts.  
All data were acquired in positive ion mode with temperature source at 300°C, 
nebuliser gas at 40 psi, desolvation gas at 50 psi. The declustering potential and the 
collision energy were adjusted with specific optimum values determined for each 
compound by infusion of standard solution. All acylcarnitines were measured by 
positive precursor ion scan of m/z 85 (scan range m/z 200-560). The specific isotope 
of each acylcarnitine was used for quantification. 
For amino acid profiling, different neutral loss scan functions were used as follows: 
neutral loss of m/z 102 for alanine (Ala), serine (Ser), proline (Pro), valine (Val), 
leucine/isoleucine (Ile), methionine (Met), histidine (His), phenylalanine (Phe), 
tyrosine (Tyr), aspartic acid (Asp) and glutamic acid (Glu), and special multiple 
reaction monitoring experiments for glycine (Gly), (132?76), ornithine (Orn) 
(189?70), arginine (Arg) (231?70), citrulline (Cit) (232?113). The specific isotope 
of each amino acid was used for quantification. The total time for 1 complete analysis 
of acylcarnitines and amino acids was 3 minutes per sample. 
Individual amino acid and acylcarnitine species were quantified by comparing their 
yield to the respective deuterated standard. In particular, the concentrations were 
automatically transferred into a ChemoView software that was developed to assist in 
data processing and quantitative calculations.  
This program determines the amino acid and acylcarnitine concentration under the 
following calculation: 
 
   Canalyte= (Ia* VIS*CIS) / (VBS IIS * RRF) 
 
Where Canalyte is the analyte concentration; Ia is the m/z signal intensity of analyte; VIS 
is the internal standard volume; CIS is the internal standard concentration; VBS is the 
blood spot volume; IIS is the m/z signal intensity of internal standard; RRF is a 
correcting factor. The same calculation was applied for dried serum spot containing 
1.2 µL of serum.  
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2.5 Results and Discussion 
 
 
By ESI-MS/MS method developed, the following amino acids were analyzed: alanine 
(Ala), serine (Ser), proline (Pro), valine (Val), isoleucine (Ile), methionine (Met), 
histidine (His), phenylalanine (Phe), tyrosine (Tyr), aspartatic acid (Asp), glutamic 
acid (Glu) (Figure 16) and basic amino acids as glycine (Gly), ornithine (Orn), 
arginine (Arg), citrulline (Cit) (Figure 17).  
The following acylcarnitines were analyzed: free carnitine (FC), acetylcarnitine (C2), 
propionylcarnitine (C3), Malonylcarnitine (C3DC), butyrilcarnitine (C4), 
methylmalonylcarnitine (C4DC), Isovalerylcarnitine (C5), Glutarylcarnitine (C5DC), 
Tiglylcarnitine (C5:1), 3-hydroxyisovalerylcarnitine (C5OH), hexanoylcarnitine (C6), 
Adipylcarnitine (C6DC), ocatnoylcarnitine (C8), Octenoylcarnitine (C8:1), 
decanoylcarnitine (C10), Decenoylcarnitine (C10:1), dodecanoylcarnitine (C12), 
Dodecenoylcarnitine (C12:1), tetradecanoylcarnitine (C14), Tetradecenoylcarnitine 
(C14:1), Tetradecadienoylcarnitine (C14:2), palmitoylcarnitine (C16), 
hexadecenoylcarnitine (C16:1), 3-hydroxyhexadecanoylcarnitine (C16OH), 
stearoylcarnitine (C18), oleylcarnitine (C18:1), 3-idroxyoleilcarnitine (C18:1 OH) 
(Figure 18). 
A decision limit (cutoff) for each analyte or analyte ratio was set on the 99.5th 
(0.05th) percentile, based on data collected and analyzed from 1200 healthy 
neonates and from 500 healthy neonates preterm (<1600 gr of weight) (Table 2).  
In addition, the ability to set flags (high and low limits) facilitated more rapid and 
accurate interpretation. Furthermore, calculation of molar ratios (concentration ratios) 
and raw ions intensities have served to improve the sensitivity of diagnostic 
screening for metabolic diseases. All cut-off values have been continuously updated 
until today in order to also minimize false-positive cases and avoid false negatives.  
A decision limit (cutoff) for each analyte or analyte ratio was set on the 99.5th 
(0.05th) percentile, based on data collected and analyzed on the serum spot samples 
based on measurements from 250 healthy subjects (Table 3). 
The diagnostic potential of this analytical method was evaluated by analysis of serum 
spot samples of patients with various types of inborn errors of metabolism. 
First example reported is a case of Phenylketonuria (Figure 19).  
As you can see in the figure 19, the amino acid profile in the bottom panel is 
characterized by a very prominent ion at m/z 222 corresponding to protonated 
molecular ion of butylated phenylalanine and a very high ratio of phenylalanine to 
tyrosine (MH+=238). Further, the concentration of phenylalanine calculated by 
Chemoview software is very high in comparison with the cut-off value. Therefore, 
these results were clearly consistent with a diagnosis of Phenylketonuria (PKU), a 
defect in the metabolism of phenylalanine caused by a deficiency of the enzyme 
phenylalanine hydroxylase or its cofactor. The concentration of phenylalanine in 
blood is affected by the influx of phenylalanine into the blood stream through dietary 
absorption, i.v. administration and protein breakdown. The rate of elimination or 
turnover of phenylalanine is affected primarily by the enzyme phenylalanine 
hydroxylase (irreversible enzyme) and secondarily through phenylalanine 
transaminase (reversible enzyme) (Figure 20). The products of phenylalanine that 
may be important in the assessment of phenylalanine metabolism include tyrosine, 
phenylpiruvic acid, phenylethalamine, phenylacetate, phenylacetylglutamine and 
hydroxyphenylacetate (Chace DH et al., 2005).  
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As with phenylalanine, a NL 102 scan function is used in measuring tyrosine (Figure 
21). The amino acid profile in the Figure 21 showed an abundant ion at m/z 238 
corresponding to the butyl derivative of tyrosine. These data were consistent with a 
diagnosis of tyrosinemia. But increased tyrosine may indicate several metabolic 
states, including three variations of tyrosinemia, types I, II and III (Figure 22) and a 
transient form, transient neonatal tyrosinemia (TNT). Therefore, additional 
investigations, using other methods, were needed to distinguish the different types of 
tyrosinemia. In this case, the diagnosis of tyrosinemia type III was confirmed by the 
detection of a significant elevation of 4-OH-phenylpiruvate and 4-OH phenyllactate in 
the patient’s urine by GC/MS analysis. This form of tyrosinemia is caused by 
deficiency of tyrosine aminotransferase enzyme (Figure 23) (Chace et al., 2005).  
The abnormal acylcarnitine profile was showed in the bottom panel of Figure 24. In 
this case there is a very prominent ion at m/z 302 corresponding to isovalerylcarnitine 
(C5), a key metabolite in the isovaleric aciduria (IVA), a disorder of intermediate 
metabolism characterized by deficiency of mitochondrial isovaleryl-CoA 
dehydrogenase (Figure 25). 
This diagnosis was confirmed by GC/MS detection of high concentration of 
isovalerylglycine in the urine of patient (Figure 26). 
The abnormal acylcarnitine profile in the bottom panel of Figure 27 showed an 
abundance of ion at m/z 274 corresponding to propionylcarnitine (C3), a key 
metabolite in two organic acidurias: Propionic aciduria (PA) and Methylmalonic 
aciduria (MMA), categorized as defects in the metabolism of the organic acyl CoA 
compounds resulting from a deficiency of either propionyl CoA carboxylase (PA) or 
methylmalonyl CoA mutase (MMA) (Figure 26).  
In order to distinguish among PA and MMA, is important to calculate the 
methylmalonylcarnitine (C4DC) concentration that, generally, is abnormal just in 
MMA. In the profile of Figure 27, the C4DC value is not alterated and therefore the 
preliminary diagnosis was PA. This result was further confirmed by GC/MS detection 
of high concentration of 3-OH-propionic acid and methylcitric acid in the urine of 
patient (Figure 29).  
As with propionic acidemia, the principle metabolite related to detection of 
methylmalonic acidemia is propionylcarnitine, as measured using MS/MS (Figure 
28). Other metabolites such as free carnitine (C0), acetylcarnitine (C2) and 
palmitoylcarnitine (C16) are important and in fact, it is quite difficult to distinguish a 
severe case of MMA from PA using MS/MS.  
The median concentration of C3 in cases of PA is generally greater than that for 
MMA, but variation is great enough to make distinction of the two particular disorders 
poor. The main features of the acylcarnitine profile that make recognition of this 
group of disorders easier are the same, however, namely, an elevated C3, C3/C2 
ratio and C3/C16 ratio.  
In the most positive cases, the increase in the concentration of the diagnostic 
metabolite, C3, is quite high. In late onset or less severe cases, however, the 
concentration of C3 may only be moderately elevated. 
Our laboratory has used and tested numerous ratios and cut-offs for C3. In our 
experience, in addition to the concentration of C3, the ratio of C3/C2 has proven to 
be the most important diagnostic measure in newborns and older infants. The ratio of 
C3/C16 is also helpful in newborns but declines in utility with age, in part because of 
the rapid decrease over time in long-chain acylcarnitines relative to short-chain 
acylcarnitines. In the diagnosis reported was very discriminate factor among PA and 
MMA the concentration of C4DC that is very high in comparison with the normal 
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value, alteration characteristic of MMA disease. This preliminary diagnosis was 
confirmed by GC/MS detection of high concentration of methylmalonic acid, 3-OH-
propionic acid and methilcitric acid in the urine of patient (Figure 29).  
In all analysis, each analyte crossing the cutoff was flagged automatically. Samples 
in which 1 or more parameters were flagged underwent a repeated analysis from the 
same sample spot.  
33 tests (1.6%) on 2016 performed until today were classified as false-positive. 
These were eliminated by repeat analysis by MS–MS on the same or a second 
sample spot and by GC–MS analysis of urine for organic acids. 
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Figure 16. Amino acids metabolic pathway analysed in our laboratory by MS/MS detection. 
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Figure 18. Acylcarnitines metabolic pathway analysed in our laboratory by MS/MS detection 
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Table 2.  Amino acid and acylcarnitine cut-off values for healthy newborn and preterm neonates. 
 
 Preterm  
(µmol/L) 
Newborn (0-1month) 
µmol/L 
   
Alanine 54-178 61-263 
Valine 26-180 30-151 
Leucine+Isoleucine+hydroxyproline 26-154 52-146 
Methionine 8-24 6-30 
Phenylalanine 10-67 21-63 
Tyrosine 5-280 15-153 
Aspartatic acid 2-44 5-42 
Glutammic acid 70-306 57-359 
Glycine 72-353 105-371 
Ornithine 3-33 6-46 
Citrulline 2-12 3-14 
Arginine 0.1-10 0.6-10 
C0 (Free carnitine) 3-49 4-44 
C2 (Acetylcarnitine) 3-34 8-47 
C3 (Propionylcarnitine) 0.01-2.7 0.04-3.18 
C3DC (Malonylcarnitine) 0.01-0.15 0.01-0.15 
C4 (Butyrylcarnitine) 0.01-0.61 0.02-0.65 
C4DC (Methylmalonylcarnitine) 0.01-0.29 0.05-0.49 
C5 (Isovalerylcarnitine) 0.01-1.00 0.02-0.29 
C5DC (Glutarylcarnitine) 0.01-0.22 0.01-0.16 
C5:1 (Tiglylcarnitine) 0-0.12 0.01-0.23 
C5OH (3-OH-Isovalerylcarnitine) 0.04-0.30 0.03-0.28 
C6 (Hesanoylcarnitine) 0-0.11 0.02-0.26 
C6DC (Adipylcarnitine) 0.01-0.10 0.02-0.15 
C8 (Octanoylcarnitine) 0.01-0.20 0.01-0.19 
C8:1 (Octenoylcarnitine) 0.01-0.20 0.01-0.30 
C10 (Decanoylcarnitine) 0-0.15 0.01-0.27 
C10:1 (Decenoylcarnitine) 0.02-0.16 0.02-0.25 
C12 (Dodecanoylcarnitine) 0.02-0.16 0.02-0.39 
C12:1 (Dodecenoylcarnitine) 0-0.09 0.01-0.23 
C14 (Myristoylcarnitine) 0.02-0.36 0.05-0.53 
C14:1 (Tetradecenoylcarnitine) 0.01-0.17 0.02-0.28 
C14:2 (Tetradecadienoylcarnitine) 0.02-0.07 0.01-0.19 
C16 (Palmitoylcarnitine) 0.25-3.16 0.52-6.05 
C16:1 (Hesadecenoylcarnitine) 0.01-0.30 0.01-0.45 
C16OH (3-OH-Hesadecanoylcarnitine) 0-0.06 0.02-0.13 
C18 (Stearoylcarnitine) 0.20-1.15 0.28-2.35 
C18:1 (Oleylcarnitine) 0.29-1.95 0.41-3.51 
C18:1OH (3-OH Oleylcarnitine) 0-0.06 0.02-0.14 
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Table 3. Amino acid and acylcarnitine cut-off values calculated on serum spot samples of healthy subjects. 
 
  
Infants (> 1 month) (µmol/L) 
  
Alanine 89-328 
Valine 63-221 
Leucine+Isoleucine+hydroxyproline 63-198 
Methionine 10-37 
Phenylalanine 33-105 
Tyrosine 32-112 
Aspartatic acid 11-45 
Glutammic acid 51-216 
Glycine 86-320 
Ornithine 13-70 
Citrulline 7-45 
Arginine 16-71 
C0 (Free carnitine) 10.0-44.7 
C2 (Acetylcarnitine) 3.5-15.4 
C3 (Propionylcarnitine) 0.07-0.65 
C3DC (Malonylcarnitine) 0.04-0.15 
C4 (Butyrylcarnitine) 0.12-0.42 
C4DC (Methylmalonylcarnitine) 0.04-0.15 
C5 (Isovalerylcarnitine) 0.05-0.24 
C5DC (Glutarylcarnitine) 0.03-0.17 
C5:1 (Tiglylcarnitine) 0.03-0.12 
C5OH (3-OH-Isovalerylcarnitine) 0.01-0.13 
C6 (Hesanoylcarnitine) 0.04-0.18 
C6DC (Adipylcarnitine) 0.02-0.11 
C8 (Octanoylcarnitine) 0.07-0.25 
C8:1 (Octenoylcarnitine) 0.03-0.40 
C10 (Decanoylcarnitine) 0.09-0.43 
C10:1 (Decenoylcarnitine) 0.08-0.32 
C12 (Dodecanoylcarnitine) 0.04-0.21 
C12:1 (Dodecenoylcarnitine) 0.04-0.20 
C14 (Myristoylcarnitine) 0.03-0.15 
C14:1 (Tetradecenoylcarnitine) 0.02-0.20 
C14:2 (Tetradecadienoylcarnitine) 0.02-0.16 
C16 (Palmitoylcarnitine) 0.01-0.23 
C16:1 (Hesadecenoylcarnitine) 0.01-0.07 
C16OH (3-OH-Hesadecanoylcarnitine) 0.01-0.05 
C18 (Stearoylcarnitine) 0.01-0.18 
C18:1 (Oleylcarnitine) 0.01-0.35 
C18:1OH (3-OH Oleylcarnitine) 0.01-0.07 
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Figure 19. Blood Amino acid profiles obtained by ESI-MS/MS analysis, scanning for a constant NL of 102 
Da. (A) Normal; (B) a case of PKU. 
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Phe = 1442 µmol/L 
      (cut-off value: 105 µmol/L) 
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Figure 20. Overview of phenylalanine metabolism as it relates to PKU. 
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Figure 21. Blood Amino acid profiles obtained by ESI-MS/MS analysis, scanning for a constant 
NL of 102 Da. (A) Normal; (B) a case of Tyrosinemia type III. 
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Figure 22.  Metabolic pathway of Tyrosinemia type II 
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Figure 23. Organic acids profiles obtained by GC/MS analysis: Tyrosinemia type III Profile vs 
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Figure 24. Blood acylcarnitine profiles obtained by ESI-MS/MS analysis, scanning for a constant PI 
of 85 Da. (A) Normal; (B) a case of IVA. 
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Figure 25. Illustration of the metabolism of selected amino acids, their production of ketogenic 
substrates, and the subsequent formation of organic acyl CoAs from these substrates. Overview of 
isovaleric aciduria, Propionic aciduria and Methymalonic aciduria. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. Organic acids profiles obtained by GC/MS analysis: Isovaleric aciduria Profile vs Normal 
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Figure 27. Blood acylcarnitine profiles obtained by ESI-MS/MS analysis, scanning for a constant PI of 
85 Da. (A) Normal; (B) A case of Propionic aciduria (PA).  
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Figure 28. Blood acylcarnitine profiles obtained by ESI-MS/MS analysis, scanning for a constant PI of 
85 Da. (A) Normal; (B) A case of Methylmalonic aciduria (MMA).  
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Figure 29. Organic acids profiles obtained by GC/MS analysis: Propionic and Methylmalonic aciduria 
Profiles vs Normal Profile 
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2.5.1 Accuracy and Precision 
 
For all samples, the method reproducibility was evaluated for each analysis by 
repeating three times the amino acids and acylcarnitines extraction and derivatization 
of the same sample. The results was very good because the average precision (area 
CV) for n=3 samples is in the range between 4 and 8. The accuracy was assessed 
by standard deviation (SD) evaluation for n=3 samples. Data were demonstrated a 
good correlation between theoretical and experimental values for all amino acids and 
acylcarnitines. 
 
 
 
2.6 Newborn Screening Quality Assurance Program 
 
 
Many factors contribute to the success of a newborn metabolic screening program. In 
actuality, blood sample collection after birth and before hospital discharge marks the 
beginning of the newborn-screening process. Proper analyses rely heavily on blood-
spot quality. Consequently, an improperly collected blood spot may disrupt the entire 
screening process for a newborn. A properly collected newborn blood specimen 
requires several elements, including suitable collection time, appropriate application 
of heel-stick blood to filter paper, sufficient drying before packaging, and timely 
shipment to the screening laboratory. A disturbance in any part of this sequence can 
lead to poor or insufficient sample analysis (Figure 30). Proper collection time avoids 
the possibility of dubious results affected by age. Careful spotting of the blood 
sample on filter paper avoids inaccurate analysis results caused by undersaturation, 
oversaturation and abraded specimens. Ample drying of a sample and its prompt 
receipt by a laboratory can prevent sample degradation (Khoury MJ et al., 2003).  
 
 
 
 
Figure 30. Examples of blood spot sample collections. 
 
 
Blood-spot materials have been developed by several organizations (e.g. “Center for 
Disease Control and Prevention” CDC) to be used in newborn-screening laboratories 
for Quality Assurance (QA) / Quality Control (QC) (Adam BW et al., 2000; Hannon 
WH et al., 1997 & Webster D et al., 1999). One of the challenges of developing 
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QA/QC materials for MS/MS arises from the complexity of multianalyte systems that 
measure not one, but many metabolites for which a positive screening result may not 
be based solely on increases in a single metabolite. Therefore, were performed a 
newborn screening quality assurance program of “Center for Disease Control and 
Prevention” (CDC), an interlaboratory quality control program for amino acids and 
acylcarnitines that artificially creates the disease state by enrichment levels of some 
amino acids or acylcarnitines in the blood spot samples. The CDC is a program to 
help state health departments and their laboratories maintain and enhance the 
quality of test results. 
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2.7 Conclusions 
 
The recent and continuing impact of tandem mass spectrometry (MS/MS) in newborn 
screening is considerable. Unquestionably, the use of MS/MS to detect metabolic 
disorders in newborns is one of the most important advancements in neonatal 
screening since the introduction of the Guthrie test for PKU because represents an 
effective tool in screening for multiple metabolic disorders in a single analysis 
(Wilcken B et al., 2003). MS/MS technology offers a new vision to newborn-screening 
programs that now have the ability to screen for 30 or more metabolic disorders in a 
single analysis from one small disk of dried blood or serum and in a few minutes. 
Our study was designed to introduce in our laboratory the MS/MS technology for 
expanded newborn screening program. This approach was revealed a reliable 
method for the early diagnosis of different inborn errors of metabolism: amino 
acidemias, fatty-acid organic disorders (FAO) and organic acidurias. Now it is 
possible to screen rapidly, simultaneously, and inexpensively many very rare 
disorders. It is very important that once the MS/MS has been set-up in the laboratory 
with an experienced team, it is much easier to add another disorder for screening 
without the need for additional sample or analysis time. Due to the robustness of this 
technology, a number of metabolic disorders with unclear natural history have been 
added to the screening programs. The number of disorders is based on experience 
with detection of increased metabolites in blood from children affected with these 
disorders, although not all have been demonstrated to be detectable in the neonate. 
The large increase in the number of inherited metabolic disorders detectable in the 
newborn period because of tandem MS screening greatly extends the possibilities of 
early, generally presymptomatic, diagnosis and treatment to minimize morbidity and 
mortality for many affected children. Therefore, whether detected presymptomatically 
(ie, by screening) or after symptoms manifest, IEM in infants and children is 
expensive to manage. In the future, the goal of our expanded newborn screening 
program will be the establishing appropriate reference intervals for subpopulations of 
newborns, the update of limits to minimize false positives and false negatives, the 
development protocols for the differential diagnosis of suspected disorders and the 
compilation of incidences of disorders. Nevertheless, is very important to consider 
that the semi-quantitative method developed is based on the analysis of metabolites 
extracted from spot samples. The extraction from spot samples, because of the 
analytical limitations that will have indicated in the next chapter, has not sufficient 
statistical power to generate high confidence in the precision of the result; therefore, 
this analytical method can be used in rapid metabolite screening where the desired 
results do not need to be highly precise but rather to answer the question of whether 
or not a metabolite falls within a certain range. In fact, in the presence of an inborn 
error of metabolism, for example the classic PKU disease, the metabolite 
concentrations exceed unequivocally their respective cut-off levels; therefore, the 
positive result is very manifest. Instead, in the follow-up of patients where is 
evaluated the efficacy therapy by phenylalanine measurement it would be better to 
use a quantitative analytical method that provides the more precise result. In 
addition, for monitoring of phenylketonuric patients is necessary to measure only 
phenylalanine and tyrosine concentrations; therefore it would be time spending and 
expensive to detect a complete metabolic profile by the classic analytical method for 
newborn screening. Development of “quantitative” analytical method for the follow-up 
of patients Phenylketonuria affected was an other aim of this research project that 
will have discussed in the next chapter. 
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Chapter 3 
 
 
3.1 Phenylketonuria (PKU) 
 
PKU (OMIM 261600) and its milder variant HPA are genetic disorders characterised 
by a deficiency in PAH (EC 1.14.16.1), an enzyme that is required to metabolise L-
Phenylalanine (L-Phe) to L-Tyrosine (L-Tyr). On the basis of blood Phe 
concentrations, PAH deficiency can be classified into classic PKU (Phe>1200 
µmol/L), mild PKU (Phe=600-1200 µmol/L) and mild HPA, where blood Phe is 
elevated above upper reference limit, but <600 µmol/L (Hanley WB, 2004). The 
decreased PAH activity found in most forms of PKU and HPA are caused by 
mutations In the PAH gene, resulting in a non-functional PAH enzyme. 
Untreated PKU is associated with an abnormal phenotype including growth failure, 
microcephaly, seizures and intellectual impairment caused by the accumulation of 
toxic by-products of Phe metabolism. The incidence of PKU or HPA is highest 
amongst Caucasian, occurring in approximately 1 in 10,000 births. PKU can be 
detected in newborn screening as performed in most Western countries, and early 
dietary treatment consisting of a low protein diet with Phe restriction can prevent the 
development of metabolic and pathological sequelae, including intellectual 
impairment. 
 
 
3.2 History of PKU 
 
PKU was first described by Asbjørn Følling, one of the first Norwegian physicians to 
apply chemical methods to the study of medicine (Centerwall SA., 2000). In 1934, the 
mother of two intellectually impaired children approached Følling to ascertain 
whether the strange musty odour of her children’s urine might be related to their 
intellectual impairment (Følling I., 1994). The urine samples were tested for a number 
of substances including ketones. When ketones are present, urine usually develops a 
red-brown colour upon the addition of ferric chloride, but in this instance the urine 
yielded a dark-green colour (Følling I., 1994). After confirming that the unusual result 
was not due to any medications and repeating the test every other day for two 
months, Følling proceeded with a more detailed chemical analysis involving organic 
extraction and purification of the responsible compound, and determination of its 
melting point (Følling I., 1994). The basic elements were quantitated by combustion, 
and an empiric formula of C9H8O3 derived (Følling I., 1994). Mild oxidation of the 
purified substance produced a compound which smelled of benzoic acid, leading 
Følling to postulate that the compound was phenylpyruvic acid (Følling I., 1994). 
There was no change in the melting point upon mixing of the unknown compound 
with phenylpyruvic acid thus confirming the mystery compound was indeed 
phenylpyruvic acid. Følling subsequently requested urine sample from 430 
intellectually impaired patients from a number of local institutions and observed a 
similar result upon addition of ferric chloride, in a further eight individuals (Følling I., 
1994). These eight individuals all presented with a mild complexion (often with 
eczema), stooping figure with broad shoulders, a spastic gait, and severe intellectual 
impairment (Følling I., 1994). Family studies of the affected individuals led to the 
suggestion of an inherited recessive autosomal trait. Dr. Følling suggested the name 
“imbecillitas phenylpyruvica” relating the intellectual impairment to the excreted 
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substance (Følling A., 1934), thereafter renamed “phenylketonuria” (Penrose L., 
Quastel JH., 1937). The discovery of PKU by Dr Asbjørn Følling was an important 
milestone in medicine. The PKU model was used to illustrate how metabolic 
abnormalities could have neurological effects and how treatment could dramatically 
affect the clinical manifestations of the disorder. The development of Guthrie’s 
screening test and dietary treatment led to the prevention of intellectual impairment in 
affected children throughout the world. Furthermore, the PKU model has since been 
used as a template to shed light on over 200 other inborn errors of metabolism 
(Applegarth DA. et al., 2000 & Raughuveer TS. et al., 2006). 
 
 
3.3 Biochemistry of PKU 
 
Phe exists as D and L enantiomers and L-Phe is an essential amino acid required for 
protein synthesis in humans (Young VR., Pellet PL., 1987) (Figure 1). 
 
 
Figure 1. Phe metabolism in humans. Intake of L-Phe is via the diet and it is recycled through amino 
acid pools. Hydroxylation by PAH with its cofactor BH4, in the presence of molecular O2, produces L-
Tyr. Alternative metabolism of L-Phe by decarboxylation or transamination produces various 
metabolites which are excreted in urine. Based on Scriver CR and Kaufman S (2001).15 
 
 
As with many other metabolites, Phe concentrations are regulated to a steady-state 
level with dynamic input and run out flux. Persistent disturbance to the flux will 
eventually result in alteration of the steady-state concentrations. Dietary intake of 
Phe along with endogenous recycling of amino acid stores are the major sources of 
Phe, whereas, utilisation or run out of Phe occurs via integration into proteins, 
oxidation to Tyr or conversion to other metabolites (Scriver CR., Kaufman S., 2001). 
The conversion of Phe to Tyr occurs by a hydroxylating system consisting of: 1) PAH, 
2) the unconjugated pterin cofactor, tetrahydrobiopterin (BH4), 3) enzymes which 
serve to regenerate BH4, namely dihydropteridine reductase and 4α-carbinolamine 
dehydratase. While the para-hydroxylation of Phe is essential for the rupture of the 
benzene ring, it is not required for further metabolism of the alanine side chain 
(Kaufman S., 1999). This alternative pathway of transamination and decarboxylation 
leads to the formation of metabolites such as phenylpiruvate, phenyllactate and o-
 66
hydroxyphenylacetate which are excreted in urine. Conversion of Phe to Tyr (Figure 
2) has two outcomes. First, it drives the endogenous production of the non-essential 
amino acid Tyr (Kaufman S., 1999). Second, the hydroxylation reaction is the rate 
limiting step for complete oxidation of Phe to CO2 and H2O and contributes to the 
pool of glucose and 2-carbon metabolites (Scriver CR., Kaufman S., 2001 & Hufton 
SE et al., 1995). 
 
 
Figure 2. Conversion of Phe to Tyr is via a pathway involving the para-hydroxylation of the benzene 
by PAH, the cofactor BH4 and molecular oxygen. 
 
 
A number of rare, related disorders due to defects in the BH4 regeneration system 
can also affect Phe homeostasis and catecholamine and serotonin biosynthesis, as 
this cofactor is common to the Phe, Tyr and tryptophan (Trp) hydroxylating enzymes 
(Blau N. et al., 2001). PAH catalyses the stereospecific hydroxylation of L-Phe, the 
committed step in the degradation of this amino acid. Phe catabolism and PAH 
activity is mainly associated with the liver, although minor activity has been 
demonstrated in rat kidney (Richardson SC. et al., 1993). In humans, the PAH 
enzyme exists as a mixture of tetramers and dimers; the monomer is about 50 KDa 
in size and is comprised of 452 amino acids (Hufton SE et al., 1995). The enzyme 
PAH requires BH4 as a cofactor, as well as molecular oxygen for its activity. 
PAH can be divided into a number of functional domains (Figure 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. The domain structure of PAH. Each PAH subunit is classified into three functional domains 
which are involved with regulation, catalytic activity, and subunit binding. 
 
The regulatory domain contains a serine residue which is thought to be involved in 
activation by phosphorylation. The catalytic domain contains a motif of 26 or 27 
(1-142)
(411-452)
(143-410)
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amino acids responsible for cofactor and ferric iron binding. The C-terminal domain is 
thought to be associated with inter-subunit binding (Hufton SE et al., 1995) (Figure 
4). 
 
 
 
Figure 4. Structural components of PAH. The catalytic domain of PAH contains a motif of 26 or 27 
amino acids which are responsible for ferric iron and cofactor (BH4) binding. Adapted from Huften IG 
et al (1995).17 
 
 
 
PAH is regulated by a number of possible mechanisms. After a protein meal, it is 
postulated that the increased Phe in the amino acid pool causes a release of 
glucagons from the pancreas (Kaufman S., 1986). 
Hepatic PAH is subject to control by cAMP-dependent protein kinase and α-
adrenergic agent stimulated Ca2+/calmodulin-dependent protein kinase 
phosphorylation–dephosphorylation processes (Richardson SC. et al., 1993). It has 
been further reported that these control mechanisms influence BH4 co-factor 
interaction with PAH (Richardson SC. et al., 1993). In addition, there is evidence that 
Phe may also be able to cause a conformational change in PAH, as well as up-
regulate cAMP activity (Hufton SE et al., 1995). X-ray crystallographic studies are 
consistent with these mechanisms (Andersen OA et al., 2002). Taken together, these 
mechanisms enable fine regulation of Phe concentrations by balancing levels 
sufficient for maintenance of protein biosynthesis while minimising tissue exposure to 
high concentrations of Phe. 
 
 
 
3.4 Genetics of PKU 
 
The human PAH gene (Figure 5) is located on chromosome 12q23.2, spans about 
171 kb and contains 13 exons (Konecki DS et al., 1992 & Lidsky AS et al., 1985). 
The total cDNA length is about 2.4 kb; it encodes for a polypeptide of 452 amino 
acids of near identical sequence to the human PAH protein, indicating little post 
translational modification (Lidsky AS et al., 1985). 
HPA can be caused by either mutations at the PAH locus, which results in PKU, or 
from mutations in a number of loci which effect BH4 synthesis and regeneration 
resulting in non-PKU HPA (Scriver CR., Kaufman S., 2001). 
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Figure 5. The basic structure of the human PAH gene. Found on the long arm of chromosome 12 
(12q23.2), the human PAH gene contains 13 exons which encode a polypeptide of 452 amino acids. 
 
 
Mutations can either be neutral with respect to phenotype, or pathogenic due to their 
disruption to enzyme structure and function. More than 500 disease-causing 
mutations have been identified in patients with PKU or HPA and recorded on the 
mutation database for PAH (PAH: Phenylalanine hydroxylase locus knowledgebase. 
http://www.pahdb.mcgill.ca/ Accessed 12 April 2007). 
The human PAH gene shows great allelic variation and pathogenic mutations have 
been described in all 13 exons of the PAH gene and its flanking region. The 
mutations can be of various types: 1) missense mutations: 62% of PAH alleles; 2) 
small or large deletions: 13%; 3) splicing defects: 11%; 4) silent polymorphisms: 6%; 
5) nonsense mutations: 5%; 6) insertions: 2%. 
Since the PAH gene is biallelic, and there are many disease causing mutations, most 
patients are compound heterozygotes (Michals-Matalon K., 2001). Some PAH 
mutations are more severe than others depending upon their effect on enzyme 
structure and function. However, the effect of PAH mutations on the clinical 
phenotype is variable (Gizewska M et al., 2003 & Kayaalp E et al., 1997). 
Compliance of dietary treatment is the primary factor which dictates blood Phe 
concentration and so plays a pivotal role in the severity of the clinical manifestations 
of PKU in an individual.  The effect of a specific mutation on enzyme function can be 
assessed through a number of approaches including enzyme assays, in vivo isotopic 
studies or by analysis of in vitro gene expression (Kayaalp E et al., 1997). Given that 
the crystal structures of the catalytic and regulatory domains have now been resolved 
to 2 Å, a fourth approach by “virtual” molecular modelling techniques (in silico) is also 
possible (Andersen OA et al., 2002).  
Large studies have shown a good correlation between the severity of mutation and 
hydroxylation rates in most individuals (Treacy EP et al., 1997). However, exceptions 
do occur and this is to be expected since hydroxylation by PAH is also dependent on 
availability of its cofactor BH4. in this regard, some PAH genotypes are known to be 
more BH4-responsive than others (BH4 – Tetrahydrobiopterin. http://www.bh4.org 
Accessed 12 April 2007). Although intelligence quotient (IQ) score is one of the most 
complex of human traits, some correlation between the severity of PAH mutations 
and IQ has been observed (Ramus SJ et al., 1993). 
The incidence of PKU in Caucasian populations is between 1 in 10,000 and 1 in 
15,000 people (Table 1). 
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It has been suggested that the high incidence of PKU in Turkey is due to the high 
prevalence of consanguinity and the low incidence seen in Finland and Japan is due 
to a pronounced negative founder effect in Finland and genetic drift in the founding of 
the Japanese island population (Guldberg P et al., 1995 & Okano Y et al., 1992). 
Untreated PKU is associated with an abnormal phenotype including growth failure, 
microcephaly, seizures and intellectual impairment caused by the accumulation of 
toxic by-products of Phe. Moreover, decreased or absent PAH activity can lead to a 
deficiency of Tyr and its downstream products, including melanin, L-thyroxine and the 
catecholamine neurotransmitters (Scriver CR., Kaufman S., 2001). 
The effect of PAH mutations on hepatic enzyme function and the resultant disruption 
to Phe homeostasis has been well described, but the major clinical effect in PKU 
relates to brain development and cognitive function (Kayaalp E et al., 1997).  
The mechanism by which high Phe concentrations result in intellectual impairment is 
yet to be clarified, but the hallmark of the neuropathology seen in both treated and 
untreated PKU seems to involve hypomyelination and demyelination (Dyer CA, 
1995). 
A number of factors have been as contributing to the neurotoxicity in PKU, including: 
Tyr deficiency, the effect of elevated Phe concentrations on transport of other 
metabolites across the blood brain barrier, and the effects of a potential and relative 
Tyr deficiency on neurochemistry and metabolism.  
Tyr is converted to L-DOPA (3,4-dihydroxy-L-Phe), a precursor of dopamine and 
other catecholamine neurochemicals. It has been suggested that the lack of PAH 
activity results in relative Tyr deficiency for the foetus, with mothers that are carriers 
for PKU possibly having limited supply of Tyr (Scriver CR., Kaufman S., 2001). 
However, there are observations which do not support this suggestion: a) restriction 
of Phe alone should not prevent the development of the phenotype, and b) 
supplementation of Tyr alone in the post-natal period does not prevent 
developmental defects nor improve neuropsychological functions. The L-type amino 
acid carrier is the sole transporter of large neutral amino acids (LNAA), which 
includes Phe, across the blood brain barrier. The competition for this carrier when 
elevated concentrations of Phe exist may have the effect of blocking transport of the 
serotonin and catecholamine precursors Tyr and Trp (Pietz J et al., 1999). Whilst 
some have proposed a strong causal link between these disrupted transport 
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mechanisms and PKU, others dispute this claim (Pietz J et al., 1999 & Hommes FA, 
1989). Magnetic resonance imaging (MRI) has shown white matter lesions in the 
brain of adult PKU patients, the size and number of which directly relate with blood 
Phe concentrations (Thompson AJ et al., 1993). Such changes have been reversed 
by lowering blood Phe levels (Cleary MA et al., 1995 & Walter JH et al., 1997). 
This has led to the establishment of Phe treatment targets (birth to 8 years, Phe 100-
350 µmol/L; older children and adults, Phe <700 µmol/L) (Australian Society for 
Inborn Errors of Metabolism. PKU handbook. Dennison B, editor. Alexandra, 
Australia: Human Genetics Society of Australasia; 2005 & Blau N, Burgard P, 2006). 
A recent meta-analysis of the cognitive profile of adolescents and adults with PKU 
compared with control subjects showed significantly reduced Full Scale IQ, 
processing speed, motor control and inhibitory abilities, and reduced performance on 
tests of attention in the PKU groups (Moyle JJ et al., 2007).  
The link between MRI changes and cognition in PKU remains elusive, although the 
use of electroencephalogram and event-related potentials has been shown to be a 
useful tool in identifying the loci of neurophysiological deficiencies during cognitive 
tasks in PKU (Moyle JJ et al., 2006). 
 
 
 
3.5 Screening and Diagnosis of PKU  
 
Since the late 1960s, and following the development of Guthrie’s biochemical assay 
for diagnosis of PKU and a number of other diseases, Australian health services 
have been conducting newborn screening programs as part of a worldwide initiative 
(Muchamore I et al., 2006).  
Collection of newborn blood by heel prick onto filter paper cards has become an 
accepted facet of newborn care throughtout the modern world (AAP Newborn 
Screening Task Force. Newborn screening: a blueprint for the future. A call for a 
national agenda on state newborn screening programs. Pediatrics 2000; 106 (Suppl): 
389-422). These blood spots can be analysed by a variety of methods to (in the case 
of PKU) measure the Phe concentration in the blood (Scriver CR., Kaufman S., 
2001).  
More recently, tandem mass spectrometry has been developed as a routine method 
for newborn screening tests.  
The cost effectiveness of this new approach has enabled an increase in the number 
of disorders screened in these programs form four (PKU, congenital hypothyroidism, 
galactosemia and cystic fibrosis) to over 20 (WA newborn Screening Program. 
Expanded newborn screening: information for health professionals. Perth, Australia: 
Departement of Health, Government of Western Australia; 2004) (Scriver CR., 
Kaufman S., 2001). 
A positive screening result identifies an infant with HPA, but it is possible that the 
increased Phe concentrations may be transient due to other non-PKU disease (e.g. 
transient 4α-carbinolamine dehydratase deficiency) or be a result of maternal HPA. 
Of the children with persistent HPA, over 98% have the condition because of 
mutations at the PAH locus (Scriver CR., Kaufman S., 2001).  
Diagnosis of HPA is made on the basis of an elevated blood Phe concentration on a 
repeat blood sample. The upper reference limit for Phe in whole blood or plasma in 
neonates is <150 µmol/L and slightly lower (<120 µmol/L) in older children (Scriver 
CR., Kaufman S., 2001).  
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The measurement of Phe metabolites in urine is not an accepted PKU screening 
method as excretion depends upon transaminase activity (which can be low in 
neonates) and great variation between blood Phe and urine metabolite 
concentrations have been demonstrated (Knox WE, 1970).  
Differential diagnosis of PKU from the disorders of synthesis or recycling of BH4 may 
involve various testing regimes including BH4 loading tests, measurement of urine 
and plasma pterin metabolites and neurotransmitter metabolites as well as blood 
spot dihydropteridine reductase measurement (Scriver CR., Kaufman S., 2001). 
Tests targeting direct enzyme measurement (PAH, 4α-carbinolamine dehydratase) 
would require tissue biopsy. 
Conventional PKU diagnosis is based on the aberrant metabolic phenotype, disease 
causing mutations and associated polymorphic haplotypes can be analysed at the 
PAH locus. PKU mutation analysis is particularly useful in the detection of carriers, 
for prenatal diagnosis.  
A wide variety of molecular genetic techniques have been utilised including Southern 
blotting, restriction enzyme digestion, detection of mutations by sequencing and 
multiplex ligation probe amplification (Desviat LR et al., 2006 & Kozak L et al., 2006). 
 
 
 
3.6 Treatment of PKU 
 
The foundation of PKU treatment is a low Phe diet which, by reducing or normalising 
Phe concentrations, prevents the development of the neurological and psychological 
changes. Since neurological changes have been demonstrated within one month of 
birth, it is recommended that dietary restriction should be started early and be 
continued through childhood when neural development is maximal (Konecki DS et 
al., 1992).  
Clinical neurological abnormalities, affected neuropsychological performance and 
brain imaging in adults with PKU has led to a consensus opinion that the PKU diet 
should be followed for life (Phenylketonuria (PKU): screening and management. NIH 
Consensus statement 2000; 17:1-33 & Management of PKU: A consensus document 
for the diagnosis and management of children, adolescents and adults with 
phenylketonuria, The National Society for Phenylketonuria (United Kingdom) Ltd; 
2004). An ever more stringent regime of Phe restriction is required for women with 
PKU contemplating starting a family, particularly during pregnancy, as elevated blood 
Phe concentrations are teratogenic towards the developing foetus. 
A low Phe diet is used for treatment with, initially, the small amounts of Phe coming 
from breast milk or commercial infant formula considered sufficient intake in babies. 
In older children, protein intake is calculated each day, whereby a child is allocated a 
certain number of grams or units of daily protein, depending upon longitudinal plasma 
Phe concentrations. Food such as eggs, milk, cheese, meat, poultry, fish, dried 
beans and legumes which are high in protein are excluded from the diet (Michals-
Matalon K, 2001). However, this regime would not normally provide enough protein 
for growth requirements and therefore, commercially available supplements of 
essential amino acids, lacking Phe, need to be taken on a daily basis. Children 
undergo regular blood Phe testing which, in concert with complete food diaries, is 
used by dieticians to make adjustments to the recommended diets (Michals-Matalon 
K, 2001). A special problem persists in the PKU diet with aspartame (L-aspartil-L-Phe 
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metyl ester) an artificial sweetener which, when metabolised, releases Phe, L-
aspartic acid and methanol. 
The benefits of the Phe-restricted, low protein diet, are clear and include: avoidance 
of the biochemical abnormality (increased Phe concentrations), improved 
neurological and psychological performance, and prevention of neurological damage. 
However, dietary treatment does not come without challenges such as: compliance 
with the diet, the requirement of social support, and risk of imbalances in essential 
dietary nutrients (Hanley WB, 2004). Blood Phe concentrations are determined by 
both the severity of the PAH mutation and by intake of Phe through dietary protein. In 
milder forms of PKU (non-PKU HPA), where there is residual enzyme activity, blood 
Phe concentrations may be only mildly elevated even under conditions of poor 
treatment diet compliance. It is accepted that the best indicator of dietary compliance 
in classical PKU is regular monitoring of blood Phe concentrations. 
The Phe-restricted diet with semi-synthetic supplementation is not without risk. PKU 
patients under dietary treatment can have low concentrations of trace elements and 
cholesterol, and some disturbance to folate metabolism as well as distortion of their 
fatty acid profile (Lucock M et al., 2002, Moseley K et al., 2002 & Schulpis KH et al., 
2004). However, it remains controversial as to whether all of these dietary 
imbalances occur as a result of insufficient intake and supplementation, or are due to 
endogenous disturbances in the biosynthesis of these essential constituents. 
The finding of low serum cholesterol concentrations in PKU patients, whilst having 
been clearly established by various groups (presumably across a wide genotypic 
spectrum) remains unexplained (Acosta PB et al., 1973, Colome C et al., 2001, 
DeClue TJ et al., 1991, Galluzzo CR et al., 1985 & Verduci E et al., 2004).This 
association could be due to dietary influences, variation in lipoprotein metabolisms 
between individuals due to their lipid controlling mechanisms, or perhaps due to 
influence of increased concentrations of Phe or its metabolites. While much work 
remains to be done, the low cholesterol concentrations in PKU may have broader 
implications to both the pathophysiology of PKU and the development of 
cardiovascular disease (CVD). Animal models have been used to demonstrate 
inhibition of sterol synthesis by various phenolic compounds (Ranganathan S, 
Ramasarma T, 1973, & Shama Bhat C, Ramasarma T, 1979). This led to work that 
investigated inhibition of a number of important enzymes involved in cholesterol 
biosynthesis; again in animal models under conditions of induced HPA (Castillo M et 
al., 1988). Dietary supplementation of L-Phe has been shown to be associated with 
inhibition of the rate determining enzyme for cholesterol biosynthesis, 3-hydroxy-3-
methylglutaryl coenzyme A reductase (EC 1.1.1.88), in the liver and brain and 
decreased concentrations of mevalonic acid.  
Decreased coenzyme Q10 (ubiquinone-10; CoQ10) concentrations have been found 
in both plasma and in lymphocytes from patients with PKU (Colome C et al., 2002 & 
Artuch R et al., 1999). CoQ10 shares a common biosynthetic pathway (the 
mevalonate pathway) to cholesterol. Apart from being a cofactor in the mitochondrial 
electron transport chain, the reduced form of CoQ10 has an important role as an 
antioxidant in both the mitochondria and lipid membranes as well as in preventing 
LDL oxidation (Colome C et al., 2002). The effect of decreased CoQ10 
concentrations and, presumably increased oxidative stress in PKU would support an 
inhibitory effect of Phe upon the cholesterol, and CoQ10 pathways. There is a 
paucity of studies investigating CVD risk and cardiovascular events in PKU. Vascular 
risk factors and homocysteine were assessed in children with PKU under dietary 
treatment and they were found to have low total cholesterol, vitamin B6, B12 and 
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folate concentrations resulting in moderate hyperhomocysteinaemia (Schulpis KH et 
al., 2002). It is possible, that the hypocholesterolaemia in adult PKU patients may 
confer a protective effect against CVD. However, an assessment of adult PKU 
patients using biochemical markers along with non-invasive imaging techniques is 
needed to test this hypothesis. Highly elevated concentrations of Phe are teratogenic 
and are a cause of increased risk of miscarriage (American Accademy of Pediatrics: 
Committee on Genetics. Maternal phenylketonuria). Specifically, the foetus can be 
affected by elevated Phe concentrations which lead to intrauterine growth 
retardation, facial dysmorphism, microcephaly, congenital heart disease and 
developmental delay and has led to families consisting of multiple children with birth 
defects and intellectual impairment (Knerr I et al., 2005; Lee PJ et al., 2005 & Shaw-
Smith C et al., 2004).  
Foetal exposure to HPA in PKU affected pregnancies is exacerbated by the 
transplacental gradient for Phe; an average foetal/maternal ratio of 1.5 is suggested 
although ratios up to 2.9 can be seen in early pregnancy when foetal development is 
maximal (Scriver CR et al., 2001). Because of the foetal morbidities associated with 
HPA, a more stringent control of blood Phe concentrations is required in mothers with 
PKU. A preconception diet is required with a Phe target interval of between 100 and 
360 μmol/L in affected mothers (Lee PJ et al., 2005). In addition, weekly monitoring 
of the Phe concentrations is advised to aid in achieving low baseline levels 
(Australian Society for Inborn Errors of Metabolism. PKU handbook. Dennison B, 
editor. Alexandra, Australia: Human Genetics Society of Australasia; 2005).  
 
 
3.7 Emerging PKU Therapies 
 
Although dietary restriction of Phe is the cornerstone of treatment for PKU, the 
practicalities of following the strict diet have led to trials of additional therapies. 
 
 
3.7.1 BH4 Therapy 
 
Recent clinical trials have shown that a subset of ‘classical’ PKU children respond to 
BH4 therapy, dependent upon their PAH gene mutation(s) (Hennermann JB et al., 
2005). Sapropterin dihydrochloride (Kuvan, Biomarin Pharma) is an orally active 
synthetic form of BH4 that has received Orphan Drug status and Fast Track 
designation for the treatment of PKU. Phase II and III clinical trials have shown that 
Kuvan is a safe and effective therapy in selected patients with HPA and mild-to-
moderate PKU who responded to a BH4 loading test (Burnett JR et al., 2007). 
 
 
3.7.2 Enzyme Replacement Therapy 
 
Unfortunately, patients with more severe forms of classic PKU and some non-PKU 
HPA do not respond to BH4 treatment, presumably because these individuals lack 
sufficient residual PAH activity for stimulation by BH4. Such nonresponders could 
benefit most from enzyme replacement therapy. Unlike BH4 treatment, enzyme 
replacement is not dependent on the PAH genotype.  
Replacement of the enzyme could be facilitated by partial liver or normal hepatocyte 
transplantation. Although liver transplantation would correct the metabolic phenotype 
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in PKU, the high risk of major surgery and lifelong immunosuppression precludes its 
routine use (Vajro P et al., 1993). 
An alternative enzyme therapy for PKU has been trialled which involves the 
substitution of PAH with Phe ammonialyase (PAL, EC 4.3.1.5), a non-cofactor 
dependent plant protein involved in Phe degradation.  
This treatment has been shown to be effective in mouse models causing modest but 
short-lived falls in Phe concentrations (Sarkissian CN et al., 1999).  
Indeed, PhenylaseTM (PAL), Biomarin Pharma is currently under investigation for the 
potential treatment of patients with PKU who do not respond to BH4. 
 
 
3.7.3 Large Neutral Amino Acid Therapy 
 
As discussed previously, it is hypothesised that competition for the L-type amino acid 
carrier by Phe with other LNAAs may occur in PKU. This hypothesis has led to LNAA 
supplementation trials (Pietz J et al., 1999).  
Increasing the blood concentrations of various LNAAs has led to reduced brain 
concentrations of Phe (Pietz J et al., 1999). Furthermore, the increased Tyr and Trp 
intake may be of benefit in disorders of BH4 regeneration.  
A new LNAA formulation (NeoPhe, Solace Nutrition) has been effective in reducing 
blood Phe concentrations (Matalon R et al., 2006). 
 
 
3.7.4 Gene Therapy 
 
Complete and persistent correction of HPA has been reported in the Pahenu2 mouse 
using somatic gene therapy, site specific genome integration of Pah cDNA and by 
liver directed recombinant adeno-associated virus vectors (Ching Z et al., 2004 & 
Harding C et al., 2006).  
Early work on gene therapy for children with PKU was considered inappropriate as 
the therapy involved administration of immunosuppressant agents to block the 
immune response to the vector so as to prolong the therapeutic effect (Ding Z et al., 
2004). These trials involved the use of recombinant adenoviral vectors. Other trials 
involving the use of recombinant retroviral vectors have been abandoned following 
the observation that these vectors may induce leukaemia-like disorders (Ding Z et al., 
2004). 
PAH-deficient (Pahenu2) mouse models have been used to trial gene transfer via a 
recombinant adeno-associated virus vector encoding the human PAH gene with 
promising results (Oh HJ et al., 2004). This vector appears to be a safer mode of 
transfer as it possesses minimal antigenicity and showed no signs of inducing liver 
damage (Oh HJ et al., 2004). However, administration of the vector would ideally be 
facilitated by a less intrusive means than via the hepatic portal vein, which was used 
in the aforementioned study. 
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3.8 Materials and Methods 
 
Patients diagnosed with phenylketonuria (PKU) following newborn screening are 
treated with a phenylalanine-restricted diet and monitored by plasma phenylalanine 
concentrations. A quantitative plasma phenylalanine method suitable for babies and 
infants requires a small sample volume, good precision at critical levels, a rapid 
turnaround time to confirm presumptive screening results, and timely management of 
the diet. Such a method must be simple and robust enough for routine use. The 
ability to measure tyrosine by the same method is an advantage, particularly for the 
management of PKU during pregnancy, and also offers a means of monitoring 
treatment of patients with tyrosinaemia. Several methods are currently available for 
the quantification of plasma phenylalanine and tyrosine, for example high-
performance liquid chromatography (HPLC). However, many of these methods 
involve relatively large sample volumes or time-consuming analysis. 
Tandem mass spectrometry has been widely advocated in screening for various 
metabolic disorders using dried blood samples. Although dried blood spots can be 
used for quantification of phenylalanine, they are not ideal for the precise 
quantification required for dietary management because of the imprecision of the 
sample volume (Holub M et al., 2006).  
Quantification in dried blood spot of metabolites is based on the fact that a disk of 3 
mm contains approximately 3.1 µl of whole blood with a hematocrit of 50.1% or 
approximately 3.2 µl with a hematocrit of 53%, but the concentrations of metabolites 
may vary between plasma and cellular compartment within a blood spot and are 
therefore amenable to changes of hematocrit. In fact, the blood volume within a given 
3 mm disk may increase significantly with increasing hematocrit levels (Holub M et 
al., 2006). Hematocrit levels in neonates vary significantly from each other and 
frequently differ from the assumed value of 50.1% or 53%. On the other hand 
premature infants especially those who are critically ill may have significantly lower 
hematocrit levels at the time of screening (Holub M et al., 2006). 
Proper analyses rely heavily on spot quality; consequently, an improperly blood spot 
preparation can lead to poor or insufficient sample analysis.  
In addition, the metabolites may be distributed according to chromatographic effects 
within the spot and therefore location of the punch may have a significant effect. In 
particular the effect of the punch position on levels of some amino acids was more 
pronounced in samples with low hematocrit, in which higher metabolite 
concentrations were found in peripheral compared to central punches due to 
chromatographic effects that take place on paper (Holub M et al., 2006). 
Because of analytical limitations, the analysis of metabolites extracted from spot 
samples has not sufficient statistical power to generate high confidence in the 
precision of the result; therefore, this assay have to consider a semi-quantitative 
analysis (Chace et al., 2001).  
This technique can be used in rapid metabolite screening where the desired results 
do not need to be highly precise but rather to answer the question of whether or not a 
metabolite falls within a certain range. In fact, in the presence of an inborn error of 
metabolism, for example the classic PKU disease, the metabolite concentrations 
exceed unequivocally their respective cut-off levels (i.e. classic PKU); therefore, the 
positive result is very manifest. In addition, when the metabolite concentrations is 
very high in comparison with cut-off values, the hematocrit and/or punch location on 
the disk do not affect decision making (Chace et al., 2001). 
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Instead, in the follow-up of patients where is evaluated the efficacy therapy by 
phenylalanine measurement it would be better to use a quantitative analytical method 
that provides the more precise result. In addition, for monitoring of phenylketonuric 
patients is necessary to measure only phenylalanine and tyrosine concentrations; 
therefore it would be time spending and expensive to detect a complete metabolic 
profile by the classic analytical method for newborn screening.  
The aim of the present study was to develop an alternative analytical method respect 
to the commonly method for neonatal screening involving butylation; it was decided to 
develop a method rely on a rapid chromatographic separation and MS/MS detection 
of underivatized phenylalanine and tyrosine. 
 
 
3.8.1 Subjects 
 
The studies were performed in 24 controls and 6 PKU patients. The patients were 
young with an age range between 4 and 10 years old. Diagnosis of Phenylketonuria 
based on the results obtained by newborn screening was confirmed by tandem mass 
spectrometry analysis using serum spot samples.  
 
 
3.8.2 Instrumentation 
 
All experiments were performed on an Agilent Series 1100 LC system (Agilent 
Technologies, Waldbronn, Germany) binary pump equipped with an HTC PAL 
autosampler. The LC system was coupled to an API 4000 triple-quadrupole mass 
spectrometer (Applied Biosystem/Sciex, Toronto, Canada) that operated in the ion 
evaporation mode with ionspray source.  
The ionspray probe was operated at a sprayer voltage of 5500 volts. The ESI source 
temperature was set to 400°C. Curtain gas back pressure 10 psi, nebulizer gas 55 
psi and desolvation gas 40 psi were applied. 
All data, acquired in the positive ion mode, were collected and processed using 
Analyst 1.4.1 software (Applied Biosystem/Sciex, Toronto, Canada). 
The multiple reaction monitoring (MRM) acquisition mode was applied for tandem 
mass spectrometric measurements of amino acids. Diagnostic fragments were 
determined for phenylalanine and tyrosine from product ion scans obtained using 
continuous flow sample infusion with a flow rate of 10 µL/min. All the source 
parameters, gas flow and collision energy values were optimized for each component 
in the MRM experiments. Applied parameters and characteristic CID fragment ions of 
the amino acids are shown in Table 2. 
Chromatographic separations were performed on a normal phase (Thermo Hypersil 
silica 50x4.6 mm I.D) chromatographic column using water/formic acid 0.1% (A) 
acetonitrile/formic acid 0.1% (B) as eluent. The chromatographic gradient profile is 
shown in the Table 3.  
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Table 2. The optimum LC-MSMS parameters for each amino acid. 
 
Amino acids Declustering potential 
(eV) 
Collision Energy 
(eV) 
MRM channel  
(Q1/Q3 m/z) 
Retention time 
 (min) 
 
Phenylalanine 45  25  166.1/120.0 1.93 
Tyrosine 50  45  182.1/91.0 1.95 
D5-Phenylalanine 40  25  171.3/125.2 1.94 
D4-Tyrosine 50  22  186.3/140.1 1.95 
 
 
 
 
 
Table 3. Chromatographic gradient profile 
 
Step Total Time (min) Flow Rate (µl/min) A (%) B (%) 
 
0 0.00 2000 5 95 
1 1.50  2000 70 30 
2 2.00 2000 70 30 
3 2.10 2000 5 95 
4 3.00 2000 5 95 
 
 
 
 
 
3.8.3 Chemicals 
 
D4-alanine as internal standard, D5-phenylalanine, D4-tyrosine and unlabeled 
phenylalanine and tyrosine, were obtained from Sigma-Aldrich (Budapest, Hungary). 
Stock solutions at 1mg/mL were made in water containing 5% of NH3 except for D4-
tyrosine where the NH3 was 10% while successive dilutions were made in methanol. 
 
 
 
 
3.8.4 Serum samples 
 
Samples were prepared by adding to 50µL of human serum, 200µL of methanol 
containing D5-phenylalanine and D4-tyrosine labelled internal standards. After that, 
they were vortexed and centrifuged at 14000 x g x 10 minutes. Finally 5µL of 
supernatant were loaded onto the LC-MS/MS system. 
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3.9 Results  
 
3.9.1 Tandem Mass Spectrometry optimization 
 
The fragmentation pattern of the protonated molecular ions ([M+H]+) of each amino 
acid under collision-induced dissociation in the tandem mass spectrometer is shown 
in Figure 6. Figure 7 shows the LC-MRM profile from each amino acid spiked in 
human serum samples 
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Figure 6. Full scans and MS/MS of phenylalanine (A), D5-phenylalanine (B), tyrosine (C), D4-tyrosine 
(D). 
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Figure 7. LC-MS/MS analysis of labelled and unlabeled (A) phenylalanine and (B) tyrosine. Identities 
and MRM channels are indicated above the LC peaks.  
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3.9.2 Assay linearity 
 
Calibration plots of analyte/internal standard peak area ratio versus the nominal 
concentration of D5-phenylalanine and D4-tyrosine in serum were constructed and 
weighted 1/x2 linear regression applied to the data.  
The dynamic ranges of calibration curves for D5-Phe and D4-Tyr were established 
on the basis of the phenylalanine and tyrosine values results from neonatal screening 
(Table 4 and Table 5). 
D5-Phe show a linear response that ranged from 25000 to 400000 ng/mL (R2= 1) 
(Figure 8); the curve for added D4-Tyr showed good linearity over the concentration 
range 250-64000 ng/mL (R2= 0.9999) (Figure 8). 
The accuracy of linearity assay was determined by comparing the nominal 
concentration values with experimental concentration values for D5-Phe and D4-Tyr. 
Results show a good correlation between the two values of concentration (Table 6 
and Table 7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8. Human serum calibration curve of D5-Phe and D4-Tyr 
 
Table 4. Dynamic range of calibration curve for 
 D5-phenylalanine 
 
 
Area ratio 
(D5-Phe/D4-Ala) 
 
Experimental 
Phe concentration 
(ng/mL) 
 
18 23890 
34 52117 
68 110293 
122 203064 
208 351084 
 
Table 5. Dynamic range of calibration curve for  
D4-tyrosine 
 
 
Area ratio 
(D4-Tyr/D4-Ala) 
 
Experimental 
Tyr concentration 
(ng/mL) 
 
0,085 234 
0,117 557 
0,173 1107 
0,254 1915 
0,428 3635 
0,832 7800 
1,639 15487 
3,321 31506 
6,001 57029 
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3.9.3 Recovery and Matrix Effect  
 
The Recovery was assessed by comparison of peak areas of analyte standards in 
matrix sample extracted with peak areas of analyte standards spiked in blank matrix 
extracted. It was determined by the following calculate: 
 
 
Recovery= A/B*100 
 
 
where A is peak area of analyte standard spiked extracted and B is peak area of 
analyte standard spiked in blank matrix post extraction. 
Data reported in Table 8 demonstrated good recovery (99.7 ± 1.0% for D5-Phe and 
98.8 ± 1.3% for D4-Tyr) (Figure 9).  
The Matrix effect was evaluated by comparison of peak areas of analyte standards in 
absence or presence of the matrix by the following calculate:  
 
 
ME=(B-A)/A*100 
 
Table 6. Accuracy of linearity assay for D5-phenyalanine 
 
 
D5-Phe  
Nominal Concentration  
(ng/mL) 
 
 
D5-Phe  
Experimental Concentration 
 (ng/mL) 
 
Accuracy (%) 
25000 23120 92 
 50000 55014 110 
100000 111921 112 
200000 197982 99 
400000 341794 85 
 
Table 7. Accuracy of linearity assay for D4-tyrosine 
 
 
D4-Tyr  
Nominal Concentration 
(ng/mL) 
 
D4-Tyr  
Experimental Concentration 
(ng/mL) 
 
 
Accuracy 
(%) 
250 234 94 
500 557 111 
1000 1107 111 
2000 1915 96 
4000 3635 91 
8000 7800 98 
16000 15487 97 
32000 31506 98 
64000 57029 89 
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where A is peak area without matrix and B is peak area with matrix. 
Data reported in Table 8 demonstrated a minimal matrix effect (17.0 ± 0.4% for D5-
Phe and 15.9 ± 0.3% for D4-Tyr) (Figure 9). 
 
 
Table 8. Recovery (A) and Matrix Effect (B) extimation of D5-phenylalanine and D4-tyrosine 
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Figure 9. Recovery (A) and Matrix Effect (B) estimation for D5-phenylaline and D4-tyrosine 
 
 
 
3.9.4 Reproducibility 
  
 
Extraction method reproducibility was evaluated by repeating the protein precipitation 
of the same spiked serum sample. Samples were run in six replicates and six 
different serum samples were used. 
The precision calculated for D5-phenylalanine and D4-tyrosine was very good (CV of 
D5-Phe 4.8% and D4-Tyr 6.5% for n=6). 
 
 
3.9.5 Quantitative analysis by LC-MRM  
 
For controls, were used 24 serum samples that had already been analyzed by 
tandem mass spectrometry analysis using spot sample and that were considered 
normal. In this control group, the mean ± SD of Phe and Tyr were 404 ± 113 µmol/L 
and 270 ± 45 µmol/L, respectively; the Phe/Tyr molar ratio in each sample was 1.50 
± 0.36.  
Figure 10 shows an example of LC-MS/MS spectrum of a serum sample that had 
been categorized as PKU. The peak area of Phe and Tyr of PKU patient is very high 
in comparison with peak area reference in the control sample. 
Results are summarized in Table 9 including results of 24 control samples. 
The Phe/Tyr ratio was calculated for each sample (Table 9).  
For all cases of PKU, the main ratio was 12 ± 9. 
AA Matrix Effect (%) 
D5-Phe 17.0 
D4-Tyr 15.9 
AA Recovery (%) 
D5-Phe 99.7 
D4-Tyr 98.8 
A B
 84
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 10. LC-MRM profile of phenylalanine and tyrosine: control vs PKU patient 
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Table 9. Quantitative analysis for phenylalanine and tyrosine in serum samples 
 
  Phenylalanine 
(ng/mL) 
Tyrosine  
(ng/mL) 
Phe/Tyr 
Ratio 
Phenylalanine  
(µmol/L) 
Tyrosine 
(µmol/L) 
Phe/Tyr 
Ratio 
 
Control 1 99278 69652 1,43 602 383 1,57 
Control 2 97721 64063 1,53 592 352 1,68 
Control 3 94303 63987 1,47 572 352 1,63 
Control 4 90488 58273 1,55 548 320 1,71 
Control 5 89045 52281 1,70 540 287 1,88 
Control 6 85597 51476 1,66 519 283 1,83 
Control 7 84766 44042 1,92 514 242 2,12 
Control 8 76403 41270 1,85 463 227 2,04 
Control 9 73332 39949 1,84 444 219 2,02 
Control 10 68700 39168 1,75 416 215 1,93 
Control 11 66067 40820 1,62 400 224 1,79 
Control 12 64905 46593 1,39 393 256 1,54 
Control 13 59576 50176 1,19 361 276 1,31 
Control 14 57896 46218 1,25 351 254 1,38 
Control 15 54819 44508 1,23 332 245 1,36 
Control 16 51720 46928 1,10 313 258 1,22 
Control 17 51782 46590 1,11 314 256 1,23 
Control 18 49523 49038 1,01 300 269 1,11 
Control 19 48420 44871 1,08 293 247 1,19 
Control 20 49243 37739 1,30 298 207 1,44 
Control 21 47770 46656 1,02 290 256 1,13 
Control 22 47986 50316 0,95 291 276 1,05 
Control 23 44727 50316 0,89 271 276 0,98 
Control 24 45955 53124 0,87 279 292 0,95 
              
AV  66668 49086 1,36 404 270 1.50 
SD 18594 8144 0,33 113 45 0.36 
              
              
Patient 1 468221 19792 24 2838 109 26,09 
Patient 2 436776 40900 11 2647 225 11,78 
Patient 3 306567 23959 13 1858 132 14,11 
Patient 4 102400 30231 3 621 166 3,74 
Patient 5 63551 41003 2 385 225 1,71 
Patient 6 210456 20004 11 1275 110 11,60 
              
AV  264662 29315 16 1604 161 12 
SD 168836 9775 8 1023 54 9 
 
 
 
 
The calibration curves and samples analysis results show a good quantitative 
response that confirms the presence of a phenylalanine hydroxylase defect identified 
by newborn screening test. 
As shown in Table 9, concentration of phenylalanine is very high in PKU patients in 
comparison with phenylalanine concentration of the controls while concentration of 
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tyrosine in the PKU patients is lower than or equal to that of control groups (Figure 
11). 
 
C
on
tro
ls
Pa
tie
nt
s 
1
Pa
tie
nt
s 
2
Pa
tie
nt
s 
3
Pa
tie
nt
s 
4
Pa
tie
nt
s 
5
Pa
tie
nt
s 
6
0
50000
100000
150000
200000
250000
300000
350000
400000
450000
500000
C
on
ce
nt
ra
tio
n 
(n
g/
m
L)
Phenylalanine and Tyrosine concentrations
 Controls vs Patients
Tyr Phe
 
 
Figure 11. Phenylalanine and tyrosine concentration in control groups and PKU patients 
 
 
Phe/Tyr ratio of PKU patients was calculated because was suggested that this ratio 
allows detection of affected infants under 24 hours of age without increasing the rate 
of false positives (Chace et al., 1998); further, the calculation of the ratio of 
phenylaline to tyrosine was shown that to be appropriate for the discrimination of 
most of the different forms of HPA (Schulze A et al., 1999).  
As shown in Figure 13, Phe/Tyr ratio of PKU patients is very high in comparison with 
Phe/Tyr ratio of control groups (Figure 12). 
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Figure 12. Phenylalanine/tyrosine ratio of control groups and PKU patients 
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So the results show that the new analytical method presented here is able to 
distinguish pathological profiles from normal profiles. 
 
 
 
3.9.6 Method Accuracy 
 
 
The accuracy of present analytical method was determined by comparing the 
individual values of phenyalanine and tyrosine in liquid serum samples with those 
obtained from the same samples by standard method for newborn screening 
involving tandem mass spectrometry analysis on dried filter paper. 
Data are reported in Table 10 and demonstrate that the concentrations of 
phenylalanine and tyrosine extracted by protein precipitation and quantified by LC-
MRM method are higher than the concentrations of phenylalanine and tyrosine 
extracted from dried serum spot and quantified by ESI-MSMS analysis in newborn 
screening.  
 
 
 
Table 10. Comparison of concentrations of phenyalanine and tyrosine in liquid serum samples (A) and in dried 
serum spot samples (B) by different extraction procedures and different analytical methods. 
 
      
 A 
 
Phe (ng/mL) 
 
Tyr (ng/mL) 
 
Phe/Tyr Ratio 
 
Phe (µmol/L) 
 
Tyr (µmol/L) 
 
Phe/Tyr Ratio 
 
Patient 1 468221 19792 24 2838 109 26 
Patient 2 436776 40900 11 2647 225 12 
Patient 3 306567 23959 13 1858 132 14 
Patient 4 102400 30231 3 621 166 4 
Patient 5 63551 41003 2 385 225 2 
Patient 6 210456 20004 11 1275 110 12 
              
AV  264662 29315 16 2448 155 17 
SD 168836 9775 8 1023 54 9 
       
 
   B Phe (ng/mL)  Tyr (ng/mL)   Phe/Tyr Ratio Phe (µmol/L) Tyr (µmol/L) Phe/Tyr Ratio 
 
Patient 1 260205 7826 33 1577 43 37 
Patient 2 211035 16198 13 1279 89 14 
Patient 3 146685 8918 16 889 49 18 
Patient 4 50820 12922 4 308 71 4 
Patient 5 30690 16380 2 186 90 2 
Patient 6 112530 8372 13 682 46 15 
              
AV  135328 11769 14 820 65 15 
SD 89516 3935 11 543 22 12 
 
 
 
As shown in Table 10, the concentrations of phenylalanine and tyrosine extracted 
from dried serum filter paper and measured by "semi-quantitative" MS/MS method 
are much lower than those of phenylalanine and tyrosine extracted from liquid serum 
by protein precipitation and determined by "quantitative" LC-MRM analytical method. 
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But an important thing to note is that the trend of phenylalanine and tyrosine of PKU 
patients is the same in both serum samples types (Figure 13). 
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Figure 13. Phenylalanine and tyrosine measurements in liquid serum and spot serum samples of PKU 
patients 
 
In addition, as shown in Table 9, the Phe/Tyr ratio values of each patient are very 
similar between the two serum sample types (Figure 14). 
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Figure 14. Phenylalanine/tyrosine ratio in liquid serum and spot serum samples of PKU patients 
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3.10 Conclusions 
 
Comparing the concentrations of phenylalanine and tyrosine of the same PKU 
patients measured with the two different analytical methods, were found significant 
differences in the concentration of each single analyte. In particular, concentrations 
of both phenylalanine and tyrosine analyzed with new analytical method are always 
about twice compared with those analyzed with the classic procedure used for 
neonatal screening. 
It is interesting to note however that the phe/tyr ratio of the same patient calculated 
with the two different methods is very similar. Therefore, both analytical methods are 
able to identify the presence of Phenylketonuria disease. 
But is probably that the semi-quantitative analytical method, using paper card, is less 
accurate and precise respect to quantitative method in liquid serum; therefore it 
underestimates the single concentrations of phenylalanine and tyrosine and so 
normalizes the analytical error through the ratio of amino acids. 
The new quantitative LC-MS/MS analysis developed is simple to execute, precise 
and reliable, with rapid analysis times. The method requires small sample volumes 
and ensures a more rapid turnaround of analysis.  
Specimen preparation is simpler and rapid (10 min) than preparation of 
phenylalanine and tyrosine in the common analytical method for newborn screening 
that, over the extraction phase, includes a butylation step (1 hour). 
This method potentially allows the analysis of screening, diagnostic and routine 
monitoring of specimens from PKU patients; therefore it represents a valid alternative 
to the common analytical method using for the diagnosis and follow-up of PKU 
patients. 
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